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ABSTRACT

THE EFFECTS OF ESTROGEN AND PHYTOESTROGENS
ON FOCAL INFARCT, PTEN, AND p-AKT
EXPRESSION IN AGED RATS

Karen Powell
August 2010
Premenopausal women have fewer and less severe strokes when compared to
postmenopausal females and aged matched males. The most obvious factor that could
account for the observed difference is the physiological activity of Estrogen. Numerous
studies over the past two decades have investigated estrogens role as a neuroprotective
agent against stroke damage. Many physiological mechanisms have been identified
supporting neuroprotection; however, data also exist to suggest that estrogen may be
harmful in certain situations such as those that produce high blood levels of estrogen or
use estrogen in older models.
The Women's Health Initiative (WHI), a large epidemiological study, found that
stroke incidence increased in women that were at least one year post menopausal and
given hormone replacement therapy (HRT) containing estrogen. This conflicting
information surrounding HRT has many women turning to soy-based phytoestrogens as
an alternative therapy. Phytoestrogens are compounds made by plants that induce some
response traditionally associated with the steroid hormone estradiol. The long term
iii

consequences of phytoestrogen consumption are presently unknown. As more
postmenopausal women choose to consume high levels of phytoestrogens either via diet
or supplements, the question arises as to how estrogen and phytoestrogens interact. The
current study is the first to explore the neuroprotective potential of phytoestrogens and
the combined effects of estrogen and phytoestrogens against permanent focal ischemia in
a middle aged model. It also explores the ability of estrogen and phytoestrogen in
regulating apoptotic vs. proliferative pathways in injured neuronal tissue.
While estrogen and phytoestrogen did produce similar effects, neither was
associated with neuroprotection. This study is important, however, because it adds
substance to the growing body of reports that E2 does not mitigate neuronal damage due
to primary infarct and it does not positively influence apoptotic pathways in aged female
rats. It also provides a more realistic model for putting into context the negative effects
documented in epidemiological studies such as the WHI, in which hypoestrogenic
women suffered more frequent and detrimental stroke events when given estrogen
replacement.
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INTRODUCTION

A brief history ofphytoestrogens and animals
Every good sheep farmer knows that one should never graze animals on pasture
dominated by dinninup, dwalganup, and yarloop (Blood and Radostits, 1989). High
consumption of these subterranean clovers can lead to infertility and a marked decrease
in lambing percentages from the normal average of 80% down to 30% (Blood and
Radostits, 1989). This phenomenon, first published in a 1946 edition of the Australian
Veterinarian Journal by Bennets et aI., is today a standard entry in large animal veterinary
medicine text books. It is classified as "poisoning caused by miscellaneous legumes".
The etiology of the infertility is the high content of biologically active estrogenic
chemicals, termed phytoestrogens (PE), found in the leguminous plants.
The presence of estrogen-like chemicals in leguminous plants holds wide-spread
implications for animals that ingest them. Some implications are advantageous, such as
the example of California quail (Callipepla califomica) switching feeding preference to
legumes high in PE to reduce fertility in times of food shortage (Leopold et aI., 1976),
while other examples of artificial introduction of legumes in the diet have proven to be a
disadvantage. Cheetahs have decreased fertility and increased liver disease when fed soybased diets in captivity (Setchell et aI., 1987). A study by Thigpen et ai. (1987) showed
that laboratory rodents fed a widely-used commercially available chow
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had uterine weight gains similar to animals fed diets containing 6 parts per billion
diethylstilbestrol, a pharmaceutical estrogen, suggesting that numerous scientific studies
might have been inadvertently influenced by the presence of PE.

What is a phytoestrogen?
Defining a PE requires one to first consider the parallel concept of "what exactly
is an estrogen"? The traditional dictionary and entry level anatomy class definition of an
estrogen is any of several steroid hormones produced chiefly by the ovaries and
responsible for promoting estrus and the development of female secondary sex
characteristics (Merrium Webster Dictionary, 2005; Marieb and Hoehn, 2009). As we
learn more about the wide array of physiological functions affected by estrogens, the
definition has become increasingly more complex. We now know that estrogens have
been found to directly or indirectly affect almost every system in the human body. They
function at the classic receptor level to upregulate gene transcription and in many nongenomic ways. It isn't just about the female in heat anymore ... and it really never was.
The difficulties of defining estrogens carryover to trying to accomplish the same task
with PE. In a 2001 publication, McLachlan defined PE as compounds made by plants
that induce some responses traditionally associated with the steroid hormone estradiol.
But as new estrogen responses are identified, the concept of PE must also continue to
expand. To date, numerous plant compounds are widely accepted as PE, including the
isoflavones genestein, daidzein, and the daidzein metabolite equol, which are studied in
this work.
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Figure 1. The chemical structures of 17P estradiol, genistein, daidzein, and equol
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Figure from Zhao, L. et al. Endocrinology 2009; 150:770-783. Reprinted with permission.

PE share a similar chemical structure (see Figure 1), specifically a phenolic group,
with vertebrate estrogens, such as

17~-estradiol

(E2). These chemicals are found in

leguminous plants in which one function is to initiate signaling pathways between the
plant and nearby nitrogen-fixing bacteria (reviewed by McLachlan, 2001). These signals
serve to recruit bacteria to the plant root hairs where they induce nodule formation for
colonization. The bacteria produce NodD proteins, which interact with the
phytochemicals to activate transcription of the genes necessary for the classic "symbiotic
nitrogen-fixing relation" in which the host plant supplies CO 2 for the bacteria and in turn
the bacteria transforms atmospheric nitrogen into a usable form for the plant (reviewed
by McLachlan, 2001). This system has many similarities with the vertebrate endocrine
system, in which chemicals are secreted, bind to receptors, and regulate transcription
(McLachlan, 2001). The substrate on which "estrogenic" chemicals can act is highly
3

conserved across vertebrate taxa, with estrogen receptors having been found in mammals,
birds, reptiles, and fish, and PE in particular have been acting on this substrate throughout
much of vertebrate evolutionary history (McLachlan, 2001).

Phytoestrogen responses that are associated with 17p-estradiol activity
There are two types of classic estrogen receptors, estrogen receptor alpha (ERa)
and estrogen receptor beta (ER~). Most PEs bind to both but have higher binding affinity
for

ER~

(Kuiper et aI., 1997). Both ERs are widely expressed in different tissue types;

however, there are some notable differences in their expression patterns. Systemically,
ERa is more prevalent in tissues traditionally associated with female reproduction
including the endometrium and breast, while ER~ is more prevalent in other organs such
as heart, lung, and kidney (Babiker et aI., 2002; Morani et aI., 2006). Both types of
receptors have been identified in the brain, with ERa predominately located in the
hypothalamus while ER~ is located in extrahypothalamic brain regions such as the
cerebral cortex and hippocampus (Shughrue and Merchenthaler, 2001). Dubal et aI.
(2006) demonstrated that ERa and ER~ are expressed differently after an ischemic event,
with ERa dramatically increased in the cerebral cortex. They also found that E2 was
unable to protect the cortex in the absence of ERa receptors, suggesting that E2-mediated
effects occur exclusively via ERa. Schreihofer (2005) found different results for PEs. At
physiological concentrations, genistein and daidzein stimulated both ERa- and ER~
dependant transcription in cell culture, but these compounds were more active at ER~.
Interestingly, the PEs did not antagonize estrogen activity at physiological
concentrations. Using hippocampal neuron cultures to study the effects of E2 and PE on
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Alzheimer's disease and memory function in postmenopausal women, Zhao et al. (2002)
found that PEs exerted a neuroprotective effect at the plasma membrane but not at the
level of neuronal mitochondrial viability when exposed to glutamate. In contrast, E2
afforded enhanced neuroprotection at both levels (Zhao et ai., 2002). E2 also promoted
neurite outgrowth and synaptogenisis while PE did not, leading the researchers to
conclude that while PEs exert some neuroprotective effects, PE and E2 are not functional
equivalents (Zhao et ai., 2002). Since PEs bind both types of receptors (Kuiper et aI.,
1997), it is plausible that the presence of PE could be antagonistic to the effects of E2, as
both would compete for the same ERa receptor. It is also plausible that through the
action of ER~, PEs could produce a partial antagonist effect over that of E2 alone. A
study of the combined effects of E2 and PEs will prove insightful.

17P Estradiol and stroke: a conflicting history
Premenopausal women have fewer and less severe strokes; a decreased risk of
mental and cardiovascular disease; experience increased cardiac output, and increased
systemic blood flow in the face of decreased resting vascular tone and myogenic
responses; but suffer higher incidences of uterine and breast cancer when compared to
postmenopausal females and aged matched males as appropriate (Prelevic et aI., 2002;
Naftolin et aI., 2004; Grodstein and Stampfer, 1995; Iafrati et aI., 1997; Karas and
Hodgin, 1999; Ohkura, 1994; Wise et aI., 2001; Dubal and Wise, 2001; Chen et aI.,
1999; Rau et aI., 2003; Choi et aI., 2004; Henderson 1993 and 1997; Nabulsi etaI., 1993;
Mendelsohn and Karas, 1999). The cardiovascular and neurologic advantages afforded

to young females diminishes with the onset of menopause (Kolominsky-Rabas et aI,
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2001; Sacco et aI., 1998; Stegmayr et aI., 1997). The most obvious factor that could
account for the observed difference is the physiological activity of E2. Numerous studies
over the past two decades have investigated the role of E2 as a neuroprotective agent
against stroke damage. The initial studies were promising. In 1988, Paganini-Hill et aI.
published some of the first data suggesting neuroprotection in women. Since 1997, a vast
amount of experimental literature has been published on this subject, including the
widely-referenced 2001 Dubal and Wise paper entitled, Neuroprotective effects of

estradiol in middle aged female rat, which demonstrates profound neuroprotective effects
of E2 at low and high doses in both young and middle aged female rats following an
ischemic event. Many physiological mechanisms have been identified supporting
neuroprotection; however, data also exist to suggest that E2 may be harmful in certain
situations. Harmful side effects seem to be consistently associated with methods that
produce high blood levels of E2 or use E2 in older models (see below). Several
mechanisms, including increased excitotoxicity, hyper-immune responses, and
miscellaneous age-specific changes have been reported that may help explain this
phenomenon.

High levels of E2 and/or estrogen in older models have been demonstrated to
promote neuron excitotoxicity. Brann et aI. (1993) found an increase in mRNA for Nmethyl D aspartate (NMDA) glutamate receptors in the cerebral cortex of rats following
E2 treatment. While Weiland et aI. (1992) showed that E2 upregulates NMDA binding
sites, Foy et aI. (1999) found that E2 enhances NMDA receptor-mediated EPSPs,
indicative of increased seizure activity, when concentrations of E2 reach 10 nmol. Gu et
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al. (1996) described an E2-mediated increase in kainite-induced currents via activation of
cyclic AMP pathways, suggesting that decreased E2 may correlate with decreased brain
activity. E2 has also been reported to decrease the uptake of L-glutamate by astrocytes,
thus contributing to excitotoxicity (Sato et al., 2003).

High levels of E2 and/or other estrogens in older models may lead to hyperimmune responses. Nordell et al. (2003) reported that E2 given to older female rats
exacerbated NMDA-induced brain inflammation as compared to younger counterparts.
Sohrabji (2005) also found that E2 treatment in young animals decreased the
inflammatory cytokine interleukin IB (Il-IB) in response to brain injury while the same
treatment in aged females increased IL-IB secretions dramatically. Looking at systemic
immune responses in whole blood to lipopolysaccharide (LPS) injections, they also found
that the aged had a heightened response to LPS and that E2 replacement further increased
TNF-a expression (Sohrabji, 2005).

E2 produces miscellaneous age-specific changes in older models. One study
found that E2 administration to aged non-overiectomized rats did not stimulate
neurotrophin, a growth factor that promotes neuronal growth and repair, even though E2
has been shown to have this effect in surgically menopaused young females (Jezierski
and Sohrabji, 2001). Similar effects were also reported for neurotrophin receptor trkA in
which E2 administered to young surgically menopaused animals upregulated trkA mRNA
and subsequent number of trkA receptors while E2 administered to the aged, naturally
menopaused animal had no effect (Gibbs, 2003; Sohrabji, 2005). Sohrabji (2005) found
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that the blood brain barrier (BBB) is more permeable in reproductively senescent animals
and that E2 replacement has no effect on this phenomenon in the aged except in the area
of the hippocampus, where it decreases BBB effectiveness even more. Aged rats have a
decrease in the number of hippocampal neurons that express ERa (Adams et aI., 2002)
and overall ERa distribution has been shown to change from a nuclear to a more
cytoplasmic localization in older human females (Hestiantoro and Swaab, 2004).

Physicians are currently discouraging the use of hormone replacement therapy
(HRT) for peri-menopausal and post-menopausal women. This recommendation is based
largely upon the findings of the Women's Health Initiative (WHI) in which breast cancer,
dementia, stroke, and cardiovascular morbidity and mortality increased in women that
were chronically hypoestrogenic (at least one year post menopausal) and given a
combination HRT of estrogen and progestin (Alving, 2004; Wassertheil-Smoller et aI.,
2003). A second phase of the WHI, utilizing estrogen only, unopposed by progesterone,
in women that had previously had hysterectomies, found that cardiovascular risk was
unaffected while stroke risk increased (Alving, 2004). Since unopposed estrogen has long
been associated with uterine cancer, only women with no uterus were included in the
study (Alving, 2004). The results of the WHI contradicts the large observational study
known as the Nurses' Health Study in which women in the menopausal transitional phase
were given HRT and experienced lower cardiovascular morbidity and mortality rates
after the initial year of therapy (Grodstein, 2001). The WHI also contradicts the vast
scientific literature available concerning the numerous benefits of E2 on an array of
neurological functions in animal models (Wise et aI., 2001, 2005).
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What accounts for the disparity between the Nurses' Health Study, the in vitro
and in vivo animal studies, and the WHI? The answer may lie, at least in part, in the
model. The WHI studied women that were aged and had undergone natural menopause,
in many cases years before the study; however, the Nurses' Health Study examined
women that were perimenopausal. Many of the in vivo animal studies reporting positive
benefits were done on young females, on males, with non-physiologic levels of E2, or
with a very acute exposure. Detrimental effects are often reported with high
supraphysiologicallevels of E2 or when models have experienced a period of
hypoestrogenism. A more realistic animal model of the peri and menopausal human
would be to use aged female retired breeder rats that had experienced the hormone
fluctuations of pregnancy, lactations, and irregular cycling common to natural aging.
Dubal and Wise (2001) used such a model. They demonstrated decreased infarct damage
from middle cerebral artery occlusion in 9-12 month-old female Sprague-Dawley rats
when given E2 replacement via slow release silastic capsule. Circulating estrogen levels
were equivalent to those of a normal estrus cycle. These results conflict with those of the
WHI. Because the Dubal and Wise model was profoundly accepted and widely cited in
the literature at the time of experimental design, the current study mirrors it. The current
study is based upon estrogens being neuroprotective with the novel aspect centering on
whether or not PE alone or in combination with estrogen were neuroprotective in a like
fashion.
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Phytoestrogens and stroke
The conflicting information and the current FDA guidelines for limited and
guarded estrogen and progestin treatment has resulted in many women receiving no HRT
and instead turning to soy-based PE as an alternative therapy (Alving, 2004; Clarkson et
aI., 1998 and 2001; Clarkson, 2002; Davis and Simpson, 1999; Huntley, 2004). The
long term consequences of PE consumption are presently unknown. Soybeans contain
mg/g amounts of isoflavones, but these levels are highly variable depending upon strain
and growth conditions (Burow et aI., 2001; Davis and Simpson, 1999). Reports of
correlations between high soy intake and decreased neoplastic incidence and
cardiovascular risk have led to increased interest in the potential health benefits of soy
(Clarkson, 2002). For example, an epidemiological study of Asian women showed a
direct correlation between soy consumption and a reduction in breast cancer incidence
(Lee et aI, 1991). These positive effects were negated when Asian women adopted a
western diet (Dixon, 2004). Other studies have focused on PE as an alternative for
postmenopausal HRT (Alving, 2004; Clarkson, 2002; Clarkson et aI., 1998 and 2001;
Davis et aI., 1995; Huntley, 200; Newton et aI., 2002). Most PE studies focus on
cardiovascular benefits (Anthony et aI., 1997; Clarkson, 2002; Clarkson et aI., 2001). An
extensive literature search revealed very few published papers concerning the effects of
PE on ischemic stroke. Most of the available literature utilizing female rats and thus,
most pertinent to this study, is from the lab of D.A. Schreihofer. In 2005, this group
compared the effects of a high PE diet (600 mg soy isoflavones/gram of food) with
estrogen replacement pellet (0.25 mg

17~-estradiol)

in overiectomized female rats (225-

250 grams). Rat age was not specified, but extrapolating from standard growth curves for
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Sprague-Dawley rats supplied by Harlan Laboratories (Indianapolis, Indiana) age can be
estimated at twelve to fifteen weeks. The animals were exposed to the diet for a total of
two weeks. The high PE diet was designed to produce blood levels equivalent to a
prototypical Asian diet, while the estrogen pellet was chosen to deliver estrogen levels
equivalent to those of proestrus (80-140 pg/ml) (Scheihofer et aI., 2005). One week post
overiectomy the animals underwent permanent middle cerebral artery occlusion
(pMCAo) via intraluminal occlusion and were sacrificed 24 hours later. Brains were
sectioned into 2mm slices using a brain matrix and stained with triphenyltetrazolium
chloride (TTC). Measured E2 blood levels at the time of sacrifice were 159 pg/ml +/- 21.
Their data showed that the animals that had been overiectomized, not provided estrogen
replacement, and placed on an isoflavone-free diet (PE-1E2 -) suffered the largest strokes.
The animals with estrogen replacement and on an isoflavone-free diet (PE -1E2+) had the
least amount of stroke damage. The animals on the high PE diet (PE +1E2-) with no
estrogen replacement had stroke damage intermediate to the other two groups. The
PE+1E2- and PE-1E2+ groups were significantly different from the PE-1E2 - group. The
study did not include a combination PE+1E2+ group. Through this experiment,
Schreihofer et aI. (2005) were the first to illustrate a beneficial role for PE against focal
ischemia; however, the authors also point out that, due to the lessened protection offered
by PE alone, PEs may not be as effective as estrogen in reducing infarct size. In 2006,
Burguete et aI. found that 8 week-old male rats that had been fed a high PE diet since
weaning had a decreased infarct following transient MCAo. The remaining literature
concerning the effects of PE on neuronal damage has been done in vitro using rat
embryonic day 18 cortices. Results suggest that soy isoflavones can reduce cell death in
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cultured cells exposed to glutamate toxicity (Zhao et aI., 2002) and calcium misregulation
by thapsigargin (Linford and Dorsa, 2002). PE results were similar to those seen with
E2.
The claims of soy as a "natural" antineoplastic and cardioprotective agent, as well
as an E2 replacement, has led to the availability of many over-the-counter, non-FDA
regulated, soy based products. Soy-rich diets, especially those containing large amounts
of tofu as are consumed in a traditional Asian diet, contain approximately 150 Ilg of
daidzein and 250 Ilg of genistein per gram of soy protein (Dixon, 2004). Once ingested,
the soy isofIavones genestein and daidzein are absorbed or daidzein is converted to equol
by intestinal microbes. Equol is significantly more estrogenic than daidzein (Dixon,
2004). Soy consumption results in measurable blood and urine concentrations of these PE
(Dixon, 2004). As more postmenopausal women on hormone replacement therapy adopt
a soy based diet, the question arises as to how E2 and PE interact. The current study is
the first to explore the neuroprotective potential of PE and the combined effects of
estrogen and PE against permanent focal ischemia in a middle aged model.

What is PTEN and p-Akt and how are they linked?
PTEN (the phosphatase and tensin homolog deleted from human chromosome 10)
is a protein tyrosine phosphatase that is known as a "tumor suppressor" gene because it
suppresses cell proliferation and promotes programmed cell death via apoptosis (Omori
et aI., 2002). This action is desirable when cell proliferation may be unregulated, such as
in epithelial neoplasias; however, it is unprotective and undesirable for amitotic cells

such as neurons. In it's active form, which is the non-phosphorylated state (Choi et aI.,
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2005), PTEN acts as a phosphoinositide 3 phosphatase which negatively regulates the
phosphoinositide 3-kinase (PI3K) pathway by catalyzing the degradation of
phosphatidylinositol (3,4,5) triphosphate, yielding phosphatidylinositol (4,5) diphosphate
(Waite et ai., 2005). Phosphatidylinositol (3,4,5) triphosphate is required for the
activation of the pro-proliferative p-Akt dependant pathway (Waite et ai., 2005). Akt is a
serine threonine protein kinase which when activated by phosphorylation (p-Akt)
promotes cell survivability in neurons via several mechanisms, including the inhibition of
death-inducing proteins such as glycogen synthase kinase 3 (GSK - 3) (Kim et ai., 2001
and Alloatti et ai., 2004) and the mitogen activated protein kinase/ c-jun N terminal
kinase (MLK3/JNK3) signaling pathways (Zhang et al. 2006). An increase in p-Akt has
also been shown to upregulate Bcl-2 protein in neurons (Pugazhenthi et al., 2000). Bcl-2
is antiapoptotic and prevents neurons from undergoing programmed cell death from
ischemic injury (Wise et aI., 2001; Choi et aI., 2004; Martinou et aI., 1994). In the case
of neuronal damage, because p-Akt prolongs cell survivability, higher levels are
protective.
Figure 2. The relationship between elevated PTEN and p-Akt levels on neuron
survi vability

t

PTEN = t neuron apoptosis

k

=1

neuron survivability

EN = t p-Akt = t neuron survivability
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The active form of Akt is well accepted to be the traditional phosphorylated form
(p-Akt). Burgering and Coffer (1995) and Franke et al.(1995) both report that
phosphorylation of residues Thr-308 and Ser -473 are required for Akt activity.
Surprisingly, the active form of PTEN is actually the unphosphorylated form.
Phosphorylation of PTEN regulates its conformational changes, thereby suppressing the
activity of PTEN by controlling the recruitment of PTEN into the PTEN-associated
complex (Adey et aI, 2000; Vazquez et aI., 2001). Choi et al. (2005) added credibility to
the hypothesis that p-PTEN is the inactive form, as they found that the activation of Akt
in the post-ischemic hippocampus of adult male rats following global ischemia mirrored
that of p-PTEN expression. Since activated PTEN inhibits activated Akt, the two forms
should not increase together.

Choi et al. (2004) showed that pharmaceutical doses of E2 greatly reduced
ischemic damage after transient MCAo in adult male Sprague-Dawley rats. Animals
administered E2 at 4 mg/kg and 10 mg/kg intraperitioneally (ip) 24 hours prior to and 5
minutes after reperfusion had significantly less infarct damage than did the control
animals. Interestingly, 1 mg/kg E2 administered ip did not significantly decrease infarct
damage over that seen in the control animals. Infarct damage paralleled measured p-Akt
levels in the ipsilateral cortex with active Akt levels significantly increased in the groups
receiving 4 and 10 mg/kg E2 over those receiving Img/kg E2 and control. This suggests
that the protective effects of E2 seen in this study may be ascribed to the ability of E2 to
upregulate Akt signaling pathways after ischemic injury. The investigators also looked at
PTEN and p-PTEN levels, but reported the results as p-PTEN being the biologically
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active form. Their results actually showed a disconnected relationship between active
PTEN and p-Akt, as both increased together in a dose proportionate manner. Although
the PTEN data are somewhat confusing, this body of work does provide evidence for E2,
albeit at very high doses, regulating pathways that ultimately determine cell fate. This
study raises the question of whether physiological, as opposed to pharmacological, levels
of estrogen in female animals could also mitigate stroke damage by regulating AktiPTEN
pathways. Studies by Omori et ai. (2002) and Choi et ai. (2005) added an additional
factor to be unraveled. Omori et ai. (2002) found that the transient focal MCAo procedure
itself upregulated PTEN activity over controls in the ischemic cortex. Choi et ai. (2005)
found that the phosphorylated forms of PTEN and p-Akt were upregulated in the
hippocampus following a transient global ischemia procedure, which leads to another
question addressed within the present study concerning what changes are actually due to
treatment vs. due to the MCAo procedure? In an attempt to answer this question, protein
measurements were taken from both ipsilateral and contralateral hemispheres, the
contralateral hemisphere providing information about the systemic treatment while the
ipsilateral, subjected to unilateral MCAo, provides information concerning the insult in
conjunction with the interventions. A previous study has reported that both p-PTEN and
PTEN are upregulated in the post ischemic brain with expression occurring
predominately in neuronal cells of the cortex, but not in astrocytes (Omori et ai., 2002).
A different study reported that upregulation of PTEN activity occurs in astrocytes, not
neurons, of the hippocampus after being subjected to transient ischemia (Choi et ai.,
2005) and kainic acid injection (Cho et ai., 2002). This brings into question the cell type
responsible for PTEN upregulation in response to ischemia.
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Several studies performed in cell cultures are relevant to the work presented in
this dissertation. Honda et al. (2000,2001) and Wilson et al. (2002) have demonstrated
that neuroprotection exerted by estrogen in primary culture cells is attributed to the
ability of E2 to activate the PI3 kinase pathway. Supportive data from Waite et al. (2005)
demonstrated a three-fold increase in PTEN levels when breast cancer cells were
stimulated with O.lnm genestein and, as would be expected, p-Akt levels decreased.
Although these studies utilized neoplastic breast cells in culture, they are relevant to the
current study because they illustrate that E2 and genestein affect the PTEN/p-Akt
pathway, albeit in an opposite manner, suggesting that E2 increases p-Akt while PE has
the opposite effect of increasing PTEN and thus decreasing p-Akt. To add to the possible
antagonist effects of E2 and PE, Stoica et aI., 2003 found that E2 increased p-Akt levels
in breast cancer cell lines by 9-fold within 10 minutes: an action that was blocked by
genestein.

Very few studies have directly looked at the roles of PE in regulating apoptotic
vs. proliferative pathways. In vivo studies of aging female systems utilizing a chronic
exposure to realistic levels of both E2 and dietary PE and their effects on the regulation
of apoptotic/proliferative pathways is merited. Such a study of the combined effects of
physiological levels of E2 and dietary soy PE may also prove insightful.

The anatomy of the middle cerebral artery and the expected outcomes of occlusion.
To fully comprehend the MCAo procedure, a good understanding of the MCA
itself is merited, as infarct studies may be adversely affected by naturally occurring
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vascular anomalies in the anatomy of the MeA and the point at which it is actually
occluded. The main trunk of the middle cerebral artery originates in the circle of Willis
and proceeds dorsally (Rubino and Young, 1988). From this point the anatomy is quite
variable. Rubino and Young (1988) attempted to define the branching patterns of the
MeA in Sprague-Dawley rats. They found that the MeA bifurcated into two major
branches, the frontal and parietal, in 95% of animals studied. In addition to these
predictable branches, two minor branches were identified in a smaller percentage of
animals. The anterioventral pyriform branch was identified in 43% of animals while the
posterioventral temporal branch was identified in 32% of animals. Seventeen percent had
all four branches, 31 % had the two major branches and one minor branch, 48% had only
the two major branches and the other 5% only had a parietal branch. They found that
when stained with Evans blue, selective occlusion of the frontal, parietal, or pyriform
branches produced a cortical lesion that was conical in shape with deep apexes.
Interestingly, selective occlusion of either the frontal or parietal branches resulted in
tertiary lesions located outside the region supplied by the branch in 56% and 86%,
respectively, of the animals studied. This study raises two critical questions concerning
the MeAo procedure. Do the anatomical differences in arterial branching lead to
variability in resulting infarct? Is the high percentage of tertiary lesions noted due to
other processes, outside of primary striatal ischemia and cortex apoptosis, that are
concurrently induced by the MeAo procedure?

The present study attempts to standardize primary infarct damage by studying

infarct size limited to the brain areas served by the parietal and frontal branches, thus
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eliminating the anatomical variance of the minor branches. To standardize occlusion, the
intraluminal suture used had a consistent preformed bulb on the end, insertion length was
measured according to body weight, and the internal carotid artery was ligated to anchor
the intraluminal suture and decrease collateral perfusion.

The frontal and parietal branches of the middle cerebral artery collectively serve
60-70% of the cortical surface of each hemisphere (Rubino and Young, 1988). The
territory served has undefined rostral limits of "much of the frontal cortex including the
piriform cortex", caudal limits of "part of the occipital cortex", and most everything in
between (Rubino and Young, 1988). Due to the published descriptions of areas served by
the two major branches of the MeA and the well-documented fact that the intraluminal
MeAo procedure does not predictably induce damage to the hippocampus, which
requires a four-vessel occlusion including the vertebral arteries, the area of infarct
damage measured in this study was limited to Bregma +2.2 through Bregma -2.8.
Bregma +2.2 lies within the frontal cortex and has a well defined piriform cortex.
Bregma -2.8 lies within the occipital lobe with minimal hippocampus but includes
caudoputamen, internal capsule, and anterior thalamus, which were described by Longa
et al. (1989) as areas rendered ischemic by intraluminal MeAo. To add credence to the
choice of using these coordinates, Rau et al. (2003) stated that this region contained the
area that undergoes injury with MeAo. Thus, the data should reflect focal cerebral
necrosis to the striatum directly served by the two main branches of the MeA and the
secondary results of ischemia to the overlying cortex. The cortex, while hypoperfused,

has the benefit of collateral circulation from the anterior and posterior cerebral arteries.
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Because of the differences in perfusion, the cells of the cortex undergo programmed cell
death rather than necrosis (Rau et aI., 2003). Given the area of the brain selected for
study, one should expect to see uniform, near complete, striatal infarct across all
experimental groups, with any variation due to treatment manifested as spared cortex.
The current study aimed to clarify the neuroprotective potential of E2 and PE alone and
in combination to selective neuronal injury associated with primary occlusion of the
striatum served by the middle cerebral artery and subsequent apoptosis of overlying
cortical neurons in middle aged females.

Goals of the present study
The present study was designed to test a more realistic model of the peri and
menopausal female than many previous studies cited above by using aged female retired
breeder rats that had experienced the hormone fluctuations of pregnancy, lactations, and
irregular cycling common to aging. The hypothesis of this study was that physiological
levels of 17/3- estradiol (E2) and dietary soy phytoestrogens (PEs) produce similar but
not additive effects on primary ischemic damage and apoptotic pathway regulation by
PTENIAkt, producing an outcome of neuroprotection in aging female systems. To test this
hypothesis, six specific questions were addressed:

1. Are physiological levels of E2 neuroprotective, as measured by infarct size
after MCAo, in reproductively senescent rats?
2. Are dietary PE neuroprotective in reproductively senescent rats?

3. What are the combined anti-ischemic effects of E2 and PE?
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4. Do physiological levels of E2 and/or dietary PE treatment alter PTEN and/or
p:..Akt expression compared to controls in the MCAo model?
5. Is PTEN/p-Akt activity altered in neurons or in astrocytes following MCAo?
6. Does the MCAo procedure upregulate PTEN/p-Akt activity as measured by
comparing IL hemisphere protein levels to those of the corresponding CL
hemisphere?

This study is important because it is the first to contribute to the understanding of
realistic levels of PE alone and in combination with E2 to mitigate occlusive stroke
damage in aged reproductively senescent rats. It also attempts to isolate primary
ischemic damage from other secondary factors by limiting the area of the brain used for
data to only the area known to be served by the middle cerebral artery in 98% of rats. In
addition, it explores the ability of PE and E2 to regulate the PTEN/Akt pathway in a
middle aged rodent model and attempts to identify cell type associated with PTENIAkt
proteins. Lastly, it will provide insight into whether or not the pMCAo procedure itself
upregulates apoptotic proteins.
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MATERIALS AND METHODS

Animals
Middle aged (10-12 months, 244-339 g body weight) female non-pregnant retired
breeder Sprague-Dawley rats ordered from Harlan (location) were maintained in a 12
hours lightl12 hours dark photoperiod (lights on 6AM). Animals were given a two week
acclimation period after arrival prior to any experimentation, during which time they
were fed a PE-reduced diet provided by the laboratory of Dr. Thomas Clarkson (Wake
Forest University) using soy protein provided by the Solae Company (St. Louis, MO),
made by subjecting soy protein to alcohol extraction to remove isoflavones, and provided
free access to water. All procedures were approved by the University of Louisville
IACUC.

Choice of model
Since rats do not have a menstrual cycle they technically cannot be said to enter
menopause; however, they do experience age-related changes in their four-day estrous
cycle (Hsueh et aI., 1979; Lu et aI., 1979). At 10-12 months of age, rats enter a period of
irregular estrus cycling followed by a period of anovulatory constant estrous that
transitions to a persistent diestrus state at approximately 25 months of age (Lu et aI.,
1979). Ovariectomizing 10-12 month old rats allow for the control of endogenous
circulating estrogen (E2) while offering a naturally aged model. Additionally, retired
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breeder rats may offer a more realistic model for women that have experienced the
extreme hormonal changes associated with pregnancy and lactation as a part of their
reproductive history over male rats or very young female rats with acute surgically
induced hypoestrogenism. Initially, Fisher rats were proposed for use in this study due to
a readily available source of retired breeders; however, they are unsuitable for the
procedure due to their cerebrovascular anatomy (Dittmar et aI., 2006). Sprague-Dawley
rats were chosen instead to more closely parallel the Dubal and Wise (2001) and
Scheihofer et al. (2005) studies.

Experimental groups
Each experimental group consisted of thirteen animals. All animals were
bilaterally ovariectomized (ovx) under isoflurane anesthesia to eliminate endogenous E2
production and then implanted with a silastic capsule made by filling 1.47 mm x 1.96 mm
silastic tubing (Dow Corning) with either micro filtered sesame oil (E2- group )(Sigma) or
189 ug/ml of

17~-estradiol

(Sigma) dissolved in microfiltered sesame oil (E2+ group).

Each capsule contained 0.6ml of oil or E2 and was sealed at each end with medical grade
silicone sealant. Each animal received two capsules implanted subcutaneously in the
scapular region. This dose is consistent with previous studies where it is reported to
produce physiological circulating E2 blood levels of approximately 20 pg/ml in SpragueDawley rats (Dubal and Wise, 2001; Rau et aI., 2003). Immediately post ovx,
buprenorphine (0.5 mg/kg) was administered via a subcutaneous route for analgesia.
Rats were provided with a diet of intact soy protein (PE+ group) or a diet of soy protein
that had been subjected to alcohol extraction of phystoestrogens (PE- group). All
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experimental animals were on the respective diet for 1 week after ovx. Fresh food was
provided daily along with free access to water.

T abIlE
e
xpenmenta groups.

Denotation

Silastic implant

Diet

Role

E2-IPE-

Oil (-)

Soy -

Negative control

E2+IPE-

E2 (+)

Soy -

E2 effects only

E2-IPE+

Oil (-)

Soy +

Phytoestrogens effects only

E2+/PE+

E2 (+)

Soy+

Combined effects of E2 and Phytoestrogens

Diet
Rats were provided with a diet of 25 grams/day containing either intact soy
protein (PE+ group) or a diet of soy protein that had been subjected to alcohol extraction
of phystoestrogens (PE- group). Both diets were prepared by the laboratory of Dr. Tom
Clarkson (Wake Forest University) using soy protein provided by the Solae Company
(St. Louis, MO), which also provided analysis of isoflavone content (Table 2). The final
diet made by the Clarkson lab consisted of 14.83% of the PE+ or PE- soy protein. The
PE+ diet was estimated to provide an intake of 144 mg of PEI1800 calories per day. This
dosage is equivalent to human intake when consuming a diet high in soy protein and has
been used successfully in several studies of rats (Clarkson et aI., 1998; Clarkson et aI.,
2001; Clarkson, 2002). Animals were provided fresh food daily along with free access to
water.
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Table 2. Composition of soy protein in the PE- and PE+ diets as made by the Solae
co mpany.
Composition
PEPE+
Protein (%)

86.8

87.6

Calcium (mgIlOOg)

110

183

Ash (%)

4.23

4.17

Fat (%)

2.25

1.91

Moisture (%)

4.4

3.7

Phosphorus (mg/100g)

740

807

Potassium (mg/lOOg)

1240

644

Sodium (mg/lOOg)

1090

824

Genistein-containing compounds ()lg/g protein)

30

2090

Daidzein-containing compounds ()lg/g protein)

30

900

Glycitein-containing compounds ()lg/g protein)

10

150

TOTAL AGL VCONE ISOFLA VONES (Jig/g protein)

40

1910

TOTAL ISOFLAVONES (Jig/g protein)

70

3140

Food consumption measurements
The food utilized in this project had a consistency similar to play dough. When
formed into a ball and placed in a wire bar rack, the animals were able to bite off pieces
with very little waste. Food consumption was measured in a subset of experimental
animals by recording initial weight of food provided and the weight of the food
remaining 24 hours later to get an estimate of daily food intake. These measurements
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were taken on an average of 8 animals per treatment group on 5 different days during the
week post ovx and prior to ischemic event. Isoflavone intake was calculated based on
grams of food consumed x 14.83% percent PE+ or PE- protein x total isoflavone content
per gram of protein.

In vivo permanent cerebral ischemia
One week post-ovariectomy and oil or E2 treatment, all animals underwent
permanent middle cerebral artery occlusion (MCAo). MCAo is a widely used procedure
in rats to mimic human occlusive stroke (Longa et aI., 1989; Wise et aI., 2001; Rau et aI.,
2003; Choi et aI., 2004). Briefly, under isoflurane anesthesia, a 4/0 monofilament suture,
coated with poly L lysine, with a standardized plastic coated tip (Doccal Company,
Redlands, CA) was inserted into the left internal carotid artery and advanced to the
middle cerebral artery. Insertion length was determined according to body weight and
measured from the bifurcation of the internal and external carotid arteries. The suture
was secured in position by placing a ligature around the internal carotid artery. This
procedure results in complete blockage of blood flow to the striatum of the left
hemisphere, which is served by MCA, with resulting necrotic cell death. In addition, it
drastically reduces blood flow to the overlying cortex but because the cortex has
collateral perfusion from branches of other cerebral arteries, it provides a model to study
programmed cell death in cortical neurons. During the MCAo procedure body
temperature was monitored with a rectal probe and maintained at normothermic (+/- 1°C)
with a heating pad. Buprenorphine (0.5 mg/kg) was administered immediately post

operatively via a subcutaneous route for analgesia.
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Histological preparation
Twenty-four hours after undergoing MCAo, rats were injected with 0.35 ml (total dose
26.25 mg ketamine/1.75 mg xylazine per animal) of a 311 ketamine (100 mg/ml)/
xylazine (20 mg/ml) mixture 1M to induce deep anesthesia, euthanised via thoracotomy,
and then intracardially perfused with 10 ml room temperature O.IM PBS followed by ice
cold 4% paraformaldehyde at a flow rate of 15 mllmin for 15 minutes per rat. Prior to
perfusion, intracardiac blood samples were drawn for analysis of E2 plasma levels and
sent to the UVa Center for Research in Reproduction Ligand Assay and Analysis Core
Laboratory (Charlottesville, V A) for fee for service ELISA testing. After perfusion the
brain was collected and cryoprotected in stepwise 12.5% to 25% sucrose in O.IM PBS at
4°C before being frozen at -80°C until subsequent Nissl staining and immunoflourescent
antibody processing occurred. Brains were sliced on a cryostat into four series of 20 Ilm
sections at -18°C. All sections were accounted for in order to calculate total thickness
between sections for infarct volume measurements.

Infarct measurements
One series of 20llm sections was subjected to a standard Nissl stain and analyzed
for striatal, cortical, and total infarct volumes. Infarcted areas did not take up the blue
Nissl stain, leaving clear demarcations between infarcted and non-infarcted tissue (see
Figure 3). Brain sections that spanned Bregma +2.2 to -2.8 were photographed on a
Leica synchroscopy microscope and saved in tagged image file format (TIFF). This
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region contains the area of the brain served by the middle cerebral artery, which includes
a portion of the frontal lobe and the lateral surface of the temporal and parietal lobes that
undergo primary injury (Rau et ai., 2003). Pictures were resized to 900 pixels and
adjusted for contrast using Adobe Photoshop version 6.0 (Adobe Systems, San Jose,
Calif., USA). Infarcted areas were measured using an image analysis system (Scion
Image v4.02, Scion Corp., Frederick, MD, USA) calibrated to 76 pixels/mm for all
pictures taken at 1.25 magnification or 60 pixels/mm for all pictures taken at 1.0
magnification. Measurements were collected on infarcted striatum, infarcted cortex, total
ipsilateral (IL) hemisphere, and total contralateral hemisphere (CL). Infarct volume data
were collected in two ways, as raw measurements in mm3 and as a percent of the total IL
hemisphere volume (%). Raw measurements allow for comparison with the results of
Dubal and Wise (2001), which is the model study for this research. The later
measurements were to account for infarct associated edema as described in Scheihofer et
al (2005) and allowed for comparison of results with the most closely matched PE study
in the literature to date. Infarct volumes were calculated by multiplying the crosssectional infarct area of striatum or cortex by thickness from one measured section to
another to arrive at infarct volume (mm3), then dividing by total cross-sectional area of IL
hemisphere to arrive at infarct volume as a % of IL hemisphere. All section measures for
each brain were then added for total mm3 or % IL hemisphere.
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Figure 3. Definition of terms used to describe infarct data
Ipsilateral
hemisphere (IL)

Contralateral
Hemisphere (CL)

striatum

cortex

P-Akt and PTEN measurements

Two other series of 20

~m

sections from six animals per experimental group were

processed for double label immunofluorescence histochemistry. Sections were from
brains that had non-infarcted cortex. Some of the original thirteen per group were not
eligible for antibody studies due to presence of infarcted cortex in the study area. The
antibody study area was defined as superficial lateral cortex, in line with the lateral
ventricles, and within Bregma +0.8 to -0.92 ( Figure 4). This area of the somatosensory
cortex was chosen for antibody study because it tended to be the variable area, either
being totally damaged or totally spared (Figure 5).
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Figure 4. Antibody target area

Figure 5. No cortex damage (A) vs. cortex damage (B) in antibody target area

Sections were blocked with normal goat serum (60 mg/rnl, Jackson
ImmunoResearch Labs, West Grove, PA., USA) for one hour at room temperature. The
sections were then incubated with primary antibodies overnight at 4°C in a combination
of a rabbit monoclonal antibody against p-Akt (Ser473, Cell Signaling Technology,
Beverly, Mass., USA, diluted 1:50), or a rabbit monoclonal antibody against PTEN
(138G6, Cell Signaling Technology, diluted 1:200) and either a mouse anti-glial fibrillary
acidic protein (Gfap) monoclonal antibody (Chemicon International, Temecula, Calif.,
USA, diluted 1:400) or mouse anti-neuronal nuclei (NeuN) monoclonal antibody
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(Chemicon, diluted 1:400). All antibody dilutions were made using a sterile antibody
dilution buffer consisting of 40mls IX PBS, 0.4 mls bovine serum albumen, and 120 ul
triton X. Sections were then incubated for 2 hours at room temperature with a mixture of
secondary antibodies consisting of Rhodamine Red conjugated goat anti-rabbit IgG
(Jackson ImmunoResearch Labs, diluted 1:500) and Fluorescein (FITC) conjugated goat
anti-mouse IgG (Jackson ImmunoResearch Labs, diluted 1:50). All incubations occurred
within a zero light humidity chamber. Prolong antifade reagent (Molecular Probes,
Eugene, OR) was applied to all sections prior to cover slipping.

T abl e 3 S ena
. I antI'b o dly treatmen t s.
Protein Marker
Cell Type Marker

Effects with Secondary Antibody

p-Akt

Gfap

red proteins with green astrocytes

PTEN

Gfap

red proteins with green astrocytes

p-Akt

NeuN

red proteins with green neurons

PTEN

NeuN

red proteins with green neurons

Immunoflourescent staining was visualized and recorded using a Zeiss laser
deconvolusion microscope using a 20x objective and quantified with the accompanying
Axiovision 4.4 image analysis software. Each of the four original treatment groups (E2IPE-, E2-/PE+, E2+IPE-, E2+IPE+) were subjected to all four antibody combinations (pAktlGfap, p-AktlNeuN, PTEN/Gfap, PTENlNeuN) so that expression of each protein in
glia vs. neurons could be assessed in each treatment group. Five images per hemisphere
(CL and IL) from three sections per slide for six different trials were analyzed resulting in
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2,880 pieces of data collected for this study. Data are reported as field area percent,
which refers to the sum of the areas of all regions (mm2 ) that meet defined
immunoflourescent criteria divided by the entire field area (mm2 ) x 100. The field area
was the same for all measurements and is determined by the aperture of the 20x lens used
for all protein data collection. In other words, this parameter measures the percent of the
field, visible with the 20x objective, occupied by fluorescing areas within a defined range
of brightness and size. Although sections were double labeled, when measuring Akt or
PTEN, only red fluorescence is measured, not both markers

Statistical analysis

Food consumption, blood estrogen levels, and changes in body weight between
ovx and MCAo data are presented as means (+/- SE). Total isoflavones consumed is
presented as average mg/day (+/- SE) intake over the six day period between ovx and
MCAo. Differences in infarct volume, p-Akt, and PTEN expression was assessed
separately by two way analyses of variance (ANOV A) with E2 and PE exposure as
independent factors using Sigma Stat software. In some cases, data did not pass tests of
equal variance or normality, and so were ranked before analysis. Separate analyses on
infarcts included striatal, cortical, and total infarct volumes, as raw measurements in
mm3, as % of ipsilateral hemisphere volume, and as specific subset data including only
animals in each group that did sustain cortex damage. (+/- SE). Subset data were
analyzed using a PROC MIXED in SAS. P- Akt and PTEN expression were analyzed
with each co-marker (NeuN, Gfap) separately. Levels were compared from the ipsilateral
hemisphere and from the ipsilateral minus the contralateral hemisphere, in which case
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post-hoc multiple pairwise comparisons using the Holm-Sidak method was warranted. A
difference of p < 0.05 was considered statistically significant. Marker effects were
analyzed using a type 3 tests of fixed effects in SAS. Pearson product moment
correlation coefficients were calculated for body weight at time of MCAo, E2 levels, and
PE consumption in relationship to cortex and total infarct volume as a % of ipsilateral
hemisphere volume (+I-SE).

32

RESULTS

Amount of phytoestrogens consumed by PE+ groups
Food consumption during the week immediately following ovx up to MCAo was
found to be consistent among the groups (see Figures 6 A-D). As expected, all groups
demonstrated a trend of increased consumption with consecutive days post ovx. Average
food intake for day one was 6 grams (+/- O.39g) with a steady increase of 2 to 3 grams
per day. By day six, the average intake had increased to 199 (+/-O.S7g).
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Figure 6 A-D. Food consumption by group by day between ovx and MCAo (mean ± SE).
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Figure 7. Food consumption across groups by day for the 7 days between ovx and MCAo
(mean ± SE).

Total isoflavones consumed by the PE+ groups reached 48.6 mg/day (+/- 2.59 mg) in the
E2-/PE+ group and 51.71 mg/day (+/- 4.21 mg) in the E2+IPE+ group (see Figure 8).
There was no significant difference between groups.

Figure 8. Isoflavone consumption (mg/day) by PE+ groups
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Circulating blood estrogens levels produced via silastic implants in E2+ groups
Circulating plasma E2 levels were measured from blood harvested at time of
animal sacrifice. The silastic implants produced average physiological blood
levels of 40 pg/ml (24-67 pg/ml), which is consistent with levels of E2 during
diestrus. The E2+IPE- and E2+/PE+ groups had very similar plasma levels of
E2, 38.65 +/- 1.88 pg/ml and 40.48 +/- 3.66 pg/ml, respectively (see figure 9).

E2+ groups
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Figure 9. Plasma E2levels in E2+ groups (mean ± SE)

Animal body weight between ovx and MCAo.
The average weight per group was similar at the time of ovx; however, much
variation existed within each group (see Table 4). As expected, the E2+ groups lost the
most weight with the E2+IPE- group losing an average of 6.6% body weight between ovx
and MCAo and the E2+/PE+ group losing an average of 6.8% body weight during the
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same time frame. The E2-IPE+ group lost the least amount with only an average 2.6%
reduction in body weight following ovx.

Table 4. Changes in body weight between ovx and MCAo.

Group

Body weight at ovx (g)

Body weight at MCAo (g)

E2-IPE-

305 +/-90

292 +/-82

E2-/PE+

305 +/-107

297 +/- 81

E2+IPE-

305 +/- 91

285 +/-73

E2+/PE+

307 +/- 60

286 +/- 51

Infarct measurements
Infarct volume data is presented in two forms, as raw measurements in mm3
and as a percent of the total IL hemisphere volume. Raw measurements allow for
comparison with the results of Dubal and Wise (2001), which is the model study for this
research. The later measurements were to account for infarct-associated edema as
described in Scheihofer et al (2005), and allowed for comparison of results with the most
closely matched PE study in the literature to date. No significant effects were detected
in striatal, cortex, or total infarct volume by two-way ANOV A using raw infarct volume
(mm

3

)

or % IL hemisphere as measures. Since there was no ANOV A effect, post hoc

multiple comparisons were not performed. Power for all analyses was low (0.05), but
with all p values above 0.7 the risk of a Type II error is very low. While all
measurements passed equal variance testing, only the striatal infarct data passed
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normality testing; thus, cortex and total infarct measurements were ranked prior to
analysis. The striatal infarct volume was essentially the same in all groups, suggesting
that the infarct procedure was equalized between groups (see Figures 10, 12 and Table 5).
Statistical analysis is addressed within the section specific to measurement type.

Raw infarct data in mm3
There was no significant difference among the ANOV A factors (E2, PE, and E2 x
PE interaction) in striatal (E2 p= 0.78, PE p= 0.80, E2 x PE P =0.73), cortex (E2 p= 0.84,
PE p= 0.96, E2 x PE P =0.72), or total infarct volume (E2 p= 0.99, PE p= 0.89, E2 x PE P
=0.71), when measuring infarct in mm 3 (see Figures 10, 12 and Table 5).

Striatal Infarct (n=13) , - - - - - - - . ,
E2 p= 0.78
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Figure 10. Striatal infarct volume (mm3) by group (mean ± SE).
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Cortex Infarct (n=13)
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Figure 11. Cortex infarct volume (mm3 ) by group (mean ± SE).
Note: These data failed normality testing and so were ranked before analysis.

Total Infarct (n=13)
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E2 x PE p= 0.71
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Figure 12. Total infarct volume (mm3) by group (mean ± SE).
Note: These data failed normality testing and so were ranked before analysis.
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E2+/PE+

. I an d totaI In
. f arct measurements In mm +
T abl e 5 M ean stnata ,cortIca
y group.
Cortical infarct volume Total infarct volume
Striatal infarct volume
Group

mm3

mm3

mm3

E2-IPE-

88.00 (+/-7.99)

46.46 (+/-15.19)

134.46 (+/-21.43)

E2-IPE+

94.77 (+/-1 3.16)

53.15 (+-15.67)

147.92 (+/-27.72 )

E2+IPE-

95.08 (+/-11.99)

49.15 (+/-18.23)

144.23 (+/- 28.48 )

E2+IPE+

94.00 (+/-11.54)

44.08 (+/-14.87)

138.08 (+/- 24.71)

Infarct data as % IL hemisphere
There was no significant difference among the ANOV A factors (E2, PE, and E2 x
PE interaction) in striatal (E2 p= 0.92, PE p= 0.92, E2 x PE P =0.84), cortex (E2 p= 0.63,
PE p= 0.93, E2 x PE p =0.89), or total infarct volume (E2 p= 0.69, PE p= 0.92, E2 x PE P
=0.98), when measuring infarct as percent IL hemisphere (see Figures 13, 14, 15 and
Table 6).

Striatal Infarct (n=13)
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Figure 13. Striatal infarct volume as a % of total ipsilateral hemisphere volume by group
(mean ± SE).
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Cortex Infarct (n=13)
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E2 x PE p= 0.89
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Figure 14. Cortex infarct volume as a % of total ipsilateral hemisphere volume by group
(mean ± SE).
Note: These data failed normality testing and so were ranked before analysis.

Total Infarct (n=13)
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Figure 15. Total infarct volume (as a % of total ipsilateral herrusphere volume) by group (mean ±
SE).
Note: These data failed normality testing and so were ranked before analysis.
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Table 6. Resulting mean ± SE of striatal, cortex, or total infarct volume (% IL
henuspJ
. here)for f our treatment groups.
Striatal Infarct Volume
Cortical infarct volume Total infarct volume
Group
% IL hemisphere

% IL hemisphere

% IL hemisphere

E2-/PE-

31.54 (+1-1.55)

14.46 (+1-4.79)

46.00 (+1-5 .64)

E2-IPE+

31.31 (+1-2.56)

15.46 (+-4.51)

46.77 (+1-6 .68)

E2+IPE-

30.85 (+1-2.47)

12.92 (+1-4.37)

43.77 (+1-5.96)

E2+IPE+

31.54 (+/-2.15)

12.69 (+/-4.17)

44.23 (+1-5.68)

Due to the non-significant results across the entire treatment groups (n=13) for the
three factors tested, two additional questions were addressed using a subset from each
original group. The first question was whether or not the presence of cortex damage
depended upon treatment group. The second question was, if cortex damage is present,
does the amount of damage depend upon treatment group? The subset to be included in
this analysis is defined in Table 7 as those animals in each group that did sustain cortex
damage. All animals with no cortex damage were excluded from the analysis testing the
second question.

Table 7 . The presence of infarcted cortex measured as % IL hemisphere by treatment
group
Cortex
E2-fPE- E2-fPE+
E2+fPE- E2+fPE+
Damaged?
NO
5
6
5
5
(zero cortex damage)

YES

8

7

8

8

TOTAL

13

13

13

13
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Table 8. Resulting mean ± SE of striatal, cortex, or total infarct volume (as a % of total
IL hemisphere volume) by group when cortex infarct is greater than zero.
Striatal Infarct Volume

Cortical infarct volume

Total infarct volume

(%IL)

(%IL)

(%IL)

E2-IPE-

32.56 (+/-1.84)

20.89 (+/-5.75)

53.44 (+/-6.71)

E2-/PE+

38.00 (+/-2.08)

28.71 (+/-3.48)

66.71 (+/-4.26)

E2+IPE-

34.88 (+/-1.94)

21.00 (+/-5.38)

55.88 (+/-6.11)

E2+IPE+

35.67 (+/-1.75)

18.33 (+/-4.98)

54.00 (+/-5.57)

Group

A logistic regression model using PROC MIXED in SAS revealed that the
presence of cortex damage did not depend upon treatment group (p=0.84). There was
also no significant factor effect (E2 p=0.78, PE p=0.78, E2/PE interaction p=0.41).
Thus, to answer the first question, the presence of cortex damage does not depend
upon treatment group.

The second question, if cortex damage is present, does the amount of damage
depend upon treatment group, was analyzed in the same manner. Resulting graphs are
presented in Figures 16, 17, and 18.

42

Striatal infarct if cortex infarct >zero
40

...
Q)
Q)

.c:

35

Co

(fj

30
E
Q)
.c:
...J
~
0

25
20

E2-/PE-

E2-/PE+

E2+/PE-

E2+/PE+

Group

Figure 16. Striatal infarct volume (as a % of total ipsilateral hemisphere volume) by
group when cortex infarct is greater than zero (mean ± SE).

Cortex infarct if cortex infarct >zero
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Figure 17. Cortex infarct volume (as a % of total ipsilateral hemisphere volume) by
group when cortex infarct is greater than zero (mean ± SE).

43

Total infarct when cortex infarct >zero
E2 p= 0.37
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E2IPE p= 0.44
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Figure 18. Total infarct volume (as a % of total ipsilateral hemisphere volume) by group
when cortex infarct is greater than zero (mean ± SE).

The resulting p values for E2, PE, and E2 x PE interaction for striatal (E2 p= 1.00,
PE p=0.12, E2IPE interaction p=0.38), cortex (E2 p=0.69, PE p=0.83, E2IPE
interaction p=0.17) , and total damage (E2 p=0.37, PE p=0.35, E2/PE interaction
p=0.44) were not significant; however, the interaction effects in the cortex did
approach significance (p=0.17) when measuring cortex damage only. Thus, to
answer the second question, if cortex damage is present, the amount of damage does
not depend upon treatment group.

The fact that both questions resulted in non-significant findings is not surprising
when one considers that the number of animals per group sustaining cortical injury
was nearly identical and when damage was present, it occurred very consistently
among groups (see Table 4 and 6).
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Table 9. Number of rats in each group by percent of cortex damage (%IL).

Percent cortex
damage

E2-IPE-

E2-IPE+

E2+IPE-

E2+IPE+

0%

5

6

5

5

1-25%

3

2

5

4

26-50%

5

5

3

4

50 -100%

0

0

0

0

Total

13

13

13

13

P-AktIPTEN measurements as field area percent of the IL hemisphere
There were no significant differences in PTEN {(PTEN/Gfap E2 p=0.68, PE p=0.55,
E2IPE interaction p=0.096) and (PTENlNeuN E2 p=0.54, PE p=0.78, E2IPE interaction

p=0.91)} or p-Akt {(p-AktlGfap E2 p=0.47, PE p=0.94, E2IPE interaction p=0.68) and
(p-AktlNeuN E2 p=0.94, PE p=0.88, E2IPE interaction p=0.71)} levels when comparing
ANOVA factors for the field area percent in the IL hemisphere (see Figures 19,20,21,
22 and Table 7). Interestingly, when double labeled with Gfap, the interaction between
E2 x PE for PTEN approaches significance (0.09). This phenomenon is not seen when
PTEN is double labeled with NeuN. This suggests that there may have been a marker
effect. A type 3 test of fixed effects performed in SAS failed to demonstrate a marker
effect for p-Akt (p=0.60) but did demonstrate a significant marker effect for PTEN
(p=0.0045). This helps explain why the level of expression of PTEN varies with
secondary marker. This may be due to the fact that both PTEN and p-Akt appear to
reside within the neurons (see Figures 23, 24, 25, 26) and some immunoflourescent signal
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could have been lost due to co-localization or physical overlap despite the red and green
immunoflourescent pigments being measured separately. Because of the marker effect, it
may be more realistic to evaluate protein expression when double labeled with Gfap and
use the NeuN data for protein localization.

It should also be noted that PTEN and p-Akt levels could only be measured on brains

with non-damaged cortex in the target area as unviable tissue would most likely contain
only denatured proteins. This eliminated the inclusion of the most damaged brains and
thus biased data towards not finding a difference.
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Figure 19. Field area percent of PTEN with Gfap in the IL hemisphere (mean ± SE).
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Figure 20. Field area percent of PTEN with NeuN in the ll..., hemisphere (mean ± SE).
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Figure 21. Field area percent of p-Akt with Gfap in the ll..., hemisphere (mean ± SE).

47

p-AktlNeuN IL Hemisphere
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Figure 22. Field area percent of p-Akt with NeuN in the IL hemisphere (mean ± SE).

Table 10. Field area percents of p-AktlPTEN with Gfap/ NeuN in the IL hemisphere
+S

PTEN/Gfap

6.83 (+/-0.34)

5.14 (+/-0.68)

5.28 (+/-0.69)

6.09 (+/-0.99)

PTENlNeuN

5.65 (+/-0.54)

5.98 (+/-1.10)

5.22 (+/-0.77)

5.37 (+/-0.81)

p-AktlGfap

5.03 (+/-0.65)

5.33 (+/-0.70)

6.05 (+/- 1.31)

5.61 (+/- 0.79)

p-AktlNeuN

5.34 (+/-0.62)

5.18 (+/-0.39)

5.05 (+/-0.64)

5.38 (+/-0.84)

Cell type associated with p-AktIPTEN
PTEN and p--Akt expression occurred predominantly in the neurons, instead of
the astrocytes, of the ischemic cortex following focal pMCAo. These proteins are
clearly expressed within the somas of neurons (Figures 24, 26) and not co-expressed with
the glial marker (Figures 23, 25).
48

Figure 23. Immunoflourescent antibody treatment for p-Akt (red) /Gfap (green) in cortex
neurons at high magnification (lOOx oil)

Figure 24. Immunoflourescent antibody treatment for p-Akt (red) lNeuN (green) in
cortex neurons at high magnification (lOOx oil)
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Figure 25. Immunoflourescent antibody treatment for PTEN (red) / Gfap (green) in
cortex neurons at low magnification (20x)

Figure 26. Immunoflourescent antibody treatment for PTEN (red) lNeuN (green) in
cortex neurons at low magnification (20x)
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Effects of MCAo procedure on P-Aktl PTEN regulation
P-Akt and PTEN levels were compared between hemispheres (IL-CL) to
determine if ischemia upregulated PTEN and/or p-Akt. If the procedure itself was
upregulating proteins, all data included in Figures 27, 28, 29, 30 and Table 8 would be
positive, indicating higher IL measurements than CL measurements. The field area
percent for the CL hemisphere was subtracted from the IL hemisphere (IL-CL) in order to
determine if the injury itself upregulated p-Akt and/or PTEN in aged models. This
phenomenon has been reported in adult female rats following global ischemia (Cai et aI.,
2009) and in adult male rats following transient MCAo (Omori et aI., 2002 and Choi et
aI., 2004) but, until this work, had not yet been explored in aged female rats following
pMCAo. Most resulting values were close to zero, indicating no procedure-specific
effects on expression.

When analyzing PTEN/Gfap the ANOV A factors of E2 and PE did not
demonstrate a significant difference (p=0.61 and p= 0.26 respectfully) but had low power
(E2 = 0.05 and PE = 0.08). A statistically significant difference was found for the E2 x
PE interaction (p=O.O 19) with a resulting power of 0.61. Post -hoc multiple pairwise
comparisons of the interaction factors showed that the E2-IPE- group differed from the
E2+IPE- group and the E2-IPE+ group, which did not differ from each other. The
E2+IPE+ group was intermediate to the others and did not differ significantly from either.
This suggests that having a single type of estrogen present prevents a difference in PTEN
levels between hemispheres. With standard error all but the E2-IPE- group are very close
to zero. The positive value of the E2-/PE- group suggests an upregulation of PTEN in the
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IL hemisphere in this model. These data failed normality testing and so were ranked
before analysis.
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Figure 27. Field area percent of PTEN with Gfap in the IL hemisphere minus the CL
hemisphere (mean ± SE).
Note: These data failed normality testing and so were ranked before analysis.

The ANOV A factors of E2 (p=0.68), PE (p=0.07), and the E2 x PE interaction (p=0.82)
for PTENlNeuN did not demonstrate significant difference . The PE did approach
significance and had a 0.3 power of performance.
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Figure 28. Field area percent of PTEN with NeuN in the IL hemisphere minus the CL
hemisphere (mean ± SE).

The ANOV A factors of E2 (p=0.29), PE (p=O. 46), and the E2 x PE interaction
(p=0.07) for p-AkUGfap did not demonstrate significant difference with respective
power of analyses of 0.06,0.05, and 0.31.
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Figure 29. Field area percent of p-Akt with Gfap in the IL hemisphere minus the CL
hemisphere (mean ± SE).
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The ANOV A factors of E2 (p=0.49), PE (p=0.17), and the E2 x PE interaction
(p=O. 71) for p-Akt/NeuN did not demonstrate significant difference. Power for all
analyses was low (0.05).
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Figure 30. Field area percent of p-Akt with NeuN in the IL hemisphere minus the CL
hemisphere (mean ± SE).

Table 11 . Field area percents of p-AktJPTEN with Gfap/ NeuN in the IL hemisphere
. h ere (mean + SE)
.
mmus
th e CL h enusPJ
E2-/PE-

E2-/PE+

E2+/PE-

E2+/PE+

IL-CL (%)

IL-CL (%)

IL-CL (%)

IL-CL (%)

PTEN/Gfap

1.65 (+/-0.52)*

-0.52 (+/-1.05)

0.52 (+/-0.10)

0.83 (+/- 0.37)

PTENlNeuN

0.41 (+/-0.28)

-0.47 (+/-0.51)

0.49 (+/-0.48)

-0.21 (+/-0.34)

p-AktlGfap

-0.75 (+/-0.69)

-0.14 (+/- 0.48)

0.85 (+/-0.42)

-0.57 (+/-0.54 )

p-AktlNeuN

0.37 (+/-0.37)

0.1 0 (+/- 0.52)

0.22 (+/-0.40)

-0.58 (+/-0.47)

Protein/marker

*- significant difference from other groups for same measure

54

Eliminating extraneous variables that could have contributed to non-significant
infarct and p -AktIPTEN data.
Since a wide range of body weights existed within groups at the time of MCAo, a
correlation analysis was merited to determine if this could have been a contributing factor
to the results. Figures 31 and 32 reveals no correlation between body weight at the time
of MCAo and resulting infarct volume. Resulting Pearson correlation value was -0.19 for
cortex infarct and -0.26 for total infarct, indicating no correlation between the two
parameters.

Body weight vs. cortex infarct volume
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Figure 31. Correlation between body weight at time of MCAo and resulting cortex
infarct volume.
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Body weight vs. total infarct volume
(%IL hemisphere)
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Figure 32. Correlation between body weight at time of MCAo and resulting total infarct
volume.

To determine if varying levels of PE consumption introduced variability into the
infarct volume data set, Pearson correlations were performed (see Figures 33 and 34).
Values were 0.04 and -0.02, respectively, indicating no correlation of the two parameters
with infarct volume.
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Figure 33. Correlation between mg isoflavones and resulting cortex infarct volume.
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Figure 34. Correlation between mg isoflavones and resulting total infarct volume.

To determine if varying E2 levels introduced variability into the infarct volume
data set, Pearson correlations were performed (see Figures 35 and 36). R values were
0.01 for cortex infarct volumes and 0.08 for total infarct volumes indicating no
correlation between circulating estrogen levels at time of sacrifice and resulting cortex or
total infarct volume.
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E2 levels (pg/ml) vs. total infarct volume
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CONCLUSIONS

This body of work was performed to provide insight into six specific questions as
follows.

1. Are physiological levels of E2 neuroprotective, as measured by infarct size after
MCAo, in reproductively senescent rats?
2. Are dietary PE neuroprotective in reproductively senescent rats?

3. What are the combined anti-ischemic effects of E2 and PE?
4. Do physiological levels of E2 and/or dietary PE treatment alter PTEN and/or pAkt expression compared to controls in the MCAo model?

5. Is PTEN/p-Akt activity altered in neurons or in astrocytes following MCAo?
6. Does the MCAo procedure upregulate PTEN/p-Akt activity as measured by
comparing IL hemisphere protein levels to those of the corresponding CL
hemisphere?

Throughout this section, findings for each question will be discussed and placed in
context with the overall hypothesis of this study.
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Are physiological levels of E2 neuroprotective in reproductively senescent rats?
The present study demonstrated that physiological levels of E2 delivered via
silastic capsule to aged female Sprague-Dawley rats does not result in neuroprotection
against pMCAo. No statistically significant differences in infarct volumes of striatum,
cortex, and total infarct measured as mm3 and % of total IL hemisphere were detected
due to treatment. These results were very surprising, as the current study was designed
based upon the established evidence (Dubal and Wise, 2001; Rau et aI., 2003; and Wise
et aI., 2001) that E2 reduces ischemic infarct size, with the intentions of comparing the
ability of PE to mimic E2. A vast amount of literature exists that attests to the
neuroprotective effects of E2 against cerebral ischemia in rats, much of which is
mentioned in the introduction of this thesis. The apparent disparity of results may be due
in part to the numerous variables between infarct studies. When one examines the stroke
research as reported in the literature, it doesn't take long to determine that there are many
variations in actual experimental design. A focal infarct, mimicking stroke, can be
induced by electrocoagulation (Bingham et aI., 2005; Carswell et aI., 2004; Farr et aI.,
2006), irradiation (Strom et aI., 2009 ), chemically (Selvamani and Sohrabji, 2008), or by
using an intraluminal monofilament suture (Choi et aI., 2004; Dubal and Wise, 2001; Rau
et aI., 2003). The suture can be inserted into the right or left middle cerebral artery
(MCA) with the left option reported as producing larger injury (Gao and Zhang, 2008).
The intraluminal suture can be left in place for a permanent MCAo (Dubal and Wise,
2001; Bingham et aI., 2005; Rau et aI., 2003) or removed after a specified time to
produce a transient MCAo (Burguete et aI., 2006; Choi et aI., 2004; Omori et aI., 2002;
Santizo et aI., 2002). The MCA can also be exposed transcranially by removing a piece
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of the zygomatic bone and the artery can be occluded with a microclip producing a
transient MCAo (Theodorsson and Theodorsson, 2005). Permanent and transient MCAos
produce two very different pathological scenarios as the transient option incorporates
reperfusion injury. An additional method for inducing brain injury is the four vessel
occlusion method (Harukuni et aI, 2001). This induces not focal ischemia, but global
ischemia and models cardiac arrest instead of a stroke event. It involves complete
hypoperfusion to the entire brain for a short duration followed by reperfusion. Animal
models vary, including several species but mainly using mice and rats. Male and female
rodents of all ages ranging from pups (Strom et aI., 2009) to 18 months of age (Strom et
aI., 2009) are used, with the majority being young adults, defined as 2-4 month old
females (Dubal and Wise, 2001; Farr et aI., 2006; Zhang et aI., 2009). A study by
Wappler et aI., 2010 found that the age of the model is a factor that worsens the neuronal
cell loss and behavioral functions of aged gerbils following transient brain ischemia.
Common characteristics of most studies are that females are overiectomized and
supplemented with some form of E2 replacement; however, the time from overiectomy to
MCAo procedure varies greatly as does the administration route and resulting dose of E2
produced. Common ways to deliver E2 include commercially available pellets (Toung et
aI. 2004; Rusa et aI, 1999; Schreihofer et aI., 2005; Theodorsson and Theodorsson, 2005;
Vergouwen et aI., 2000), injections (Pelligrino et aI, 1998; Choi et al. 2005; Park et aI.,
2005; Raval et aI., 2007), silastic capsules (Dubal et aI. 1998; Dubal and Wise, 2001),
and recently minipumps (Zhang et aI., 2009). The timing of E2 replacement ranges from
immediately (Dubal et aI. 1998; Dubal and Wise, 2001) to 10 weeks post overiectomy
(Zhang et aI., 2009) and doses vary by over a thousand fold as some are administered in
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microgram/kg body weight concentrations (Dubal and Wise,

2001~

Rau et aI., 2003)

while other are given in milligram/kg body weight concentrations (Carswell et aI., 2004;
Choi et aI. 2005).

Strom et aI. (2009) recently published a review of E2 effects on rat cerebral
ischemia. They attempted to only include studies sharing a set criterion including rat
models that have undergone ischemic injury with E2 administration as the only variable
between groups. A placebo group and direct measurement of brain damage also had to
be included in the design. Their search revealed sixty-six studies meeting these criteria.
Of the sixty-six, fifty-six concluded that E2 was neuroprotective but surprisingly four
articles reported no difference between placebo and E2 treatments (Farr et aI., 2006;
Goodrow et aI., 2005; Santizo et aI., 2002; Vergouwen et aI., 2000) and six articles
reported detrimental effects with E2 (Bingham et aI., 2005; Carswell et aI., 2004; Gordon
et aI., 2005; Harukuni et aI., 2001; Theodorsson and Theodorsson, 2005; Yong et aI.,
2005). Neuroprotection from E2 was mainly seen in studies involving young female rats
that had undergone surgically induced, thus instant, menopause with immediate low level
E2 replacement (Dubal and Wise, 2001 and Stom et aI., 2010). In contrast, detrimental
effects were most often seen following the use of high pharmaceutical doses of E2 or
commercial pellets that have been found to produce a "supraphysiological burst" of E2
when first administered (Singh et aI., 2008 and Strom et aI., 2010), or following
prolonged E2 deprivation. Interestingly, a recent article by Lebesgue et aI. (2010)
showed that E2, administered intracerebroventricularly, immediately post tMCAo, was
neuroprotective in middle aged rats that were chronically E2 deprived. This suggests that
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the ability to respond to E2 is maintained both in aged and hypoestrogenic animals and
that the problem may arise from the logistics of a systemic delivery system.

Since this study found no significant neuroprotection by E2, a closer examination
of similarities between it and those studies reported in the literature as finding no effect
or a negative effect is merited. Farr et al. (2006), found no significant differences in
infarct volume, functional recovery in behavioral tests, or gross synaptogenesis between
placebo and E2 treatment groups when overiectomized 12 week old female rats were
subjected to focal ischemia via intracranial electrocoagulation of MCA. A key point of
this study was that rats experienced a two week E2 deprivation prior to MCA. They
received E2 through a pellet. Harukuni et al. (2001) found that five minutes of ischemia
produced by four-vessel occlusion resulted in equivalent neuronal damage in 12 week old
overiectomized, overiectomized plus E2, or intact females. Ten minutes of ischemia
produced significantly worse injuries in the overiectomized +E2 group and intact group
over the animals that were overiectomized and not supplemented with E2. They also
demonstrated a highly significant correlation between increased cell loss and E2 level,
with higher levels of E2 (within physiological range:s 30 pg/ml) being associated with
increased neuronal cell death. Gordon et al. (2005) overiectomized two month old female
rats and immediately implanted them with either an E2 or placebo pellet. Two weeks
later all underwent pMCAO via intraluminal suture and were sacrificed twenty-four
hours later. Brains were cut into 6[!m sections, stained, and resulting infarct measured
from 12.5 mm anterior to 0.05 mm posterior of the interauralline. The E2 group
experienced infarcts that were 118 % greater than placebo (area of brain measured not
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listed). They also measured a byproduct of lipid peroxidation, 4 hydroxynonenol (4
HNE), which damages proteins in neurons and glial cells. They found almost none of this
compound in the contralateral hemisphere of study animals but found it significantly
increased in E2-treated infarcted cortex. The volume of cortex tissue with increased 4
HNE extended beyond the primary infarct suggesting that mechanisms of damage extend
beyond primary infarct area and more than one mechanism of damage is initiated by
MCAo. Also, the ratio of 4 HNE positive cells to infarcted cells was greater in the E2
group than placebo, suggesting that E2 could be causing an overexaggerated response to
the injury. Carswell et al. (2004) found that overiectomized four month old female rats
provided immediate E2 replacement via pellets in two concentrations, 0.025 and 0.25 mg
per animal, suffered increased infarcts that were dose dependant following pMCAo by
electrocoagulation. Rats with the lower dose pellet averaged 65% larger infarcts than
placebo and those with the higher dose had a 96% larger infarct than placebo. Similarly,
Bingham et al. (2005) followed this up by using the same experimental design, except in
twelve week old female rats, and found that both low and high dose treatment groups
experienced significantly more damage than placebo. A study by Theodorrson and
Theodorrson (2005), found that infarct damage was doubled in the E2 treatment group vs.
placebo when the brain was measured from bregma +4 through -4 in 12-14 week old
female rats that were overiectomized with immediate E2 replacement by pellet.
Selvamani and Sohrabji (2008) compared damage from a chemical-induced MCA
occlusion model in middle aged (9-11 month) retired breeders and 6 to 7 month old
active breeder Sprague-Dawley rats. This procedure caused a gradual constriction of the
MCA lasting around 16 hours followed by reperfusion. All animals had previously been
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overiectomized with immediate E2 replacement via pellet. They found that both cortical
and striatal lesions were significantly greater in older females compared to younger
females. These were also significantly worse in the middle aged group with E2 versus
the middle aged control groups. These results suggest that E2 exacerbated the lesions
over placebo in middle aged animals. Zhang et aI. (2009) found that three month old
female Sprague-Dawley rats overiectomized with immediate E2 supplement via a
subcutaneous minipump had significantly lower infarct volumes, decreased NADPH
oxidase activity, and superoxide levels, in specific regions of the hippocampus than
placebo when subjected to global ischemia. However, when deprived of E2 for 10 weeks
and implanted with pump one week before being subjected to global ischemia, all
protection was lost. While cell survivability reached 50% (extrapolated from graph) in
the animals receiving immediate E2 treatment, it dropped to 10% (extrapolated from
graph) in animals deprived of E2 ten out of eleven weeks prior to ischemic event. In this
instance there was no difference between placebo and the long term E2-deprived group
treated with delayed E2 replacement.

These studies suggest that E2 loses its ability to protect neurons against ischemic
damage after long term deprivation (2 weeks-lO weeks of hypoestrogenism) and in older
animals, which are likely to have experienced periods of E2 deprivation as a normal
aging process. Delivery of E2 via a slow release pump doesn't negate neuroprotection
associated with E2 after a 10 week deprivation (Zhang et aI., 2009). Such findings are in
agreement with studies such as the WHI in which many participating women were
several years beyond menopause (Alving, 2004). Negative effects are also commonly
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seen with very high replacement doses of E2 after prolonged deprivation; however, this
study did not use such doses. Relevant findings to this study are that older animals
provided physiological levels of E2 via slow release replacement have been found to be
at no advantage over controls and in some instances suffer worse damage.

Additional effects of 17-P Estradiol that may confound infarct measurements
Several articles published after this study was designed and implemented cite both
protective and damaging effects of E2 that are not directly associated with a primary
response to infarct but yet may very well influence measured infarct volumes in ancillary
ways. These findings are relevant to explaining discrepancies between the results of the
current study to those of the model study by Dubal and Wise (2001). For example,
Brown et al. (2008) found that low dose E2 administered via silastic capsule
downregulated nitric oxide production resulting from induced NOS2 gene expression in
mice following permanent MCAo in both sham and injured cortex, suggesting that one
mechanism by which E2 can exert neuroprotection is by downregulating critical
components of the inflammatory response. Along the same lines, Park et al. (2005)
found that, compared to age matched ovx females, young 2-3 month old intact females
and ovx females with E2 replacement expressed lower levels of inducible nitric oxide
synthase (iNOS), ICAM 1 ( a leukocyte adhesion molecule) and NADPH subunit
gp91 phox (presumed free radical producer), suggesting less inflammation. Crosby et al.
(2007) found that activated caspase 12 was significantly increased in infarcted areas in
E2 treated animals compared to controls. Caspase 12 is deregulated by endoplasmic

reticulum stress and leads to increased apoptotic cell death. A corresponding increase in
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terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick endlabeling (tunnel) staining in infarcted areas was also found, indicating increased DNA
fragmentation. These studies all support the ability of E2 to regulate various components
of inflammation following ischemic insult. In some instances E2 appears to be antiinflammatory while in others it actually increases inflammatory responses and apoptosis.
All above mentioned studies were performed in young animals. A very recent study by
Traub et aI., 2009 demonstrated neuroprotection from E2 delivered via a commercial
pellet in aged rats that were subjected to transient global ischemia eight weeks post ovx.
This discrepancy may be due in part to the mechanisms underlying neuronal death
following focal and global ischemia models as well as, the differences in E2 action in the
areas of the brain primarily damaged by the two procedures (Traub et aI., 2009). Acute
inflammation may play more of a role in damaged from focal ischemia than global
ischemia (Traub et aI., 2009 and Suzuki et aI., 2007).

The secondary effects of E2-

mediated inflammatory changes on aged, E2-deprived brains following focal permanent
MCAo is still to be determined but are most likely real and present.

Comparing this study to the widely-referenced Dubal and Wise 2001 paper
. When comparing the model of ischemia studied in this project to all studies
currently in the literature, not many exist with enough similarities for outright
comparison. In fact, a thorough review of the literature revealed only one study that
utilized silastic capsules for E2 delivery and performed permanent MCAo via
intraluminal occlusion on middle aged rats. That study is the widely-referenced 2001

Dubal and Wise paper entitled Neuroprotective effects of estradiol in middle agedfemale
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rats, the very one upon which this study was based, which demonstrates neuroprotective

effects of E2 at low and high doses in both young and middle aged female rats. Both
studies used 9-12 month old females that were overiectomized and immediately
implanted with silastic capsules containing either a total concentration of 180 ug/ml

17~

estradiol (Sigma St. Louis, MO) or vehicle (sesame oil, Sigma). One week post
ovariectomy and implant treatment, all rats underwent permanent MeAo via the
intraluminal suture method (Longa et al. 1989). Unlike the Dubal and Wise study, this
study used a commercially available suture with preformed bulb for MeAo in an attempt
to decrease the variability introduced by forming the bulb via melting the tip of the suture
(Gordon et al., 2005). Dubal and Wise (2001) do not reference creating such a bulb on
the end of the intraluminal suture, but they do describe using a fire tipped suture in mice
in a later paper (Dubal et al., 2006). In the present study, suture insertion length was
measured from the bifurcation of the carotid artery and determined by animal weight.
Dubal and Wise (2001) do not mention exact length of suture inserted. They do reference
inserting the suture until resistance is felt.

A major deviation from the Dubal and Wise study is the amount of brain tissue
that was measured for infarct. Dubal and Wise sectioned the entire brain (bregma +4.2
through -3.8) into lmm sections using a brain matrix while this study sectioned the brains
into 20l1m sections and calculated total infarct from bregma +2.2 through -2.8 only. The
rationale for using this area is two-fold: it reduces the variability introduced by the
anatomical differences in the branching pattern of the MeA, as 95% of animals have the

frontal and parietal branches that serve this area, thus providing a better measurement of
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primary infarct damage with subsequent apoptosis of the cortex. In turn, it should
decrease the contributions of inflammation and other E2-mediated confounds by
eliminating brain tissue adjacent to but not part of the primary infarct territory.
Following permanent MCAo, cells of the striatal core undergo necrotic cell death
primarily as a result of hypoxia-induced glutamate excitotoxicity (Storm-Mathisen et aI.,
1992; Zerangue and Kavanaugh, 1996; Danbolt, 2001). The overlying cortex is less
severely damaged due to collateral circulation and thus is subjected to cell death via
apoptotic rather than necrotic pathways. Because apoptotic cell death is the outcome of
intracellular events occurring inside a single cell and does not involve the release of
chemicals into the interstitial area, primary apoptosis doesn't significantly contribute to
the expansion of the infarct beyond the affected area (Crosby et aI, 2007). Thus any
cortex damage resulting from primary infarct-induced apoptosis should not be outside of
the primary area of damage, although it is realized that other factors may be at work
within this area of cortex. While it is impossible to tease out all the processes that are
occurring within the primary affected cortex, one thing seems certain: any damage that is
measured outside the area of the MCA territory cannot be attributed to primary infarct or
infarct-induced apoptosis and must be mediated by other pathways and processes. Thus, a
whole brain measurement could be misleading, as it accounts for numerous effects. The
current study attempted, as much as possible, to tease out primary damage from other
secondary contributors by limiting the measured area to that part of the brain served by
the MCA in 95% of animals and the corresponding overlying cortex. This difference in
amount of brain measured may contribute to the stark difference in reported outcomes
between the current study and that of Dubal and Wise (2001). Interestingly, bregma +2.2
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through -2.8 is the area later used and described by the same lab group (Rau et aI., 2003)
as the region that contains the area that undergoes injury with MCAo.
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The low E2 results are essentially the same between the two studies. The largest
difference is in the oil treatment cortex and thus total infarct volume. The average
volume of the total ipsilateral hemisphere within the measured area of bregma +2.2 to 2.8 in this study was 279 mm 3 . To reach a total infarct volume of 250 mm 3 would require
an average 90% infarct throughout the entire measured area. Thus the differences seen in
the oil treatment infarct volume may be attributed to secondary neuronal death occurring
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in brain areas rostral and caudal to the primary area served by the MCA and captured via
the extended measurement area utilized by Dubal and Wise (2001).

Are dietary phytoestrogens neuroprotective in reproductively senescent rats?
The present study demonstrated that dietary levels of PE equivalent to a prototypical
Asian diet fed to aged female Sprague-Dawley rats did not result in neuroprotection
against pMCAo. Infarct volumes of striatum, cortex, and total infarct did not differ from
control groups. This contrasts the findings of Schreihofer et al. (2005) in which similar
PE diets were found to be neuroprotective following pMCAo in young (age extrapolated
from weight) female Sprague-Dawley rats. In the same study, isoflavones were found
to be less effective than estrogen in reducing infarct size after MCAo in young rats.
In light of those findings, it is not surprising that, given that no significant E2 effect was found in
the present study, PE treatment was not found to be protective. No other references were
found that examined the effects of dietary PEs against ischemic injury in an aged animal
model. A few studies exist that have studied the possible mechanisms for the PE-based
neuroprotection reported in young animals. Lovekamp-Swam et al. (2007) tested
several parameters found to be affected by estrogens in stroke recovery (Rau et al.,2003).
They found that in female rats (age not specified) subjected to transient MCAo, PE
decreased DNA fragmentation, reduced caspase 3 activity, and increased the expression
of antiapoptotic genes in the ischemic area. The remaining literature concerning the
effects of PE on neuronal damage has been done in vitro using rat embryonic day 18
cortices. Results suggest that soy isoflavones can reduce cell death in cultured cells

exposed to glutamate toxicity and oxygen glucose deprivation (Scheihofer and Redmond,
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2009). PE results were similar to those seen with E2. The present study hypothesized
similar results as those obtained by Schreihofer et al. (2005). While the methods were
essentially the same, accountable differences include animal age, reproductive status, and
estrogen levels. Recent literature attests to these variables being major factors in the
ability of estrogen or estrogen-like compounds to negate ischemic injury.

What are the combined anti-ischemic effects of E2 and PE?
There were no apparent agonistic or antagonistic effects of PE on E2 or vice versa
on infarct size, as the combination was statistically no different from either treatment
alone or from control. This was the first study to examine the combined effects in an
aged model following pMCAo.

Do physiological levels of E2, dietary PEs, or ischemia alter PTEN and/or Akt
expression?
No change was seen in PTEN or p-Akt levels following E2, PE, or a combination
with one exception: PTEN when double labeled with Gfap did demonstrate a significant
difference in levels between the IL and CL hemispheres in the E2-/PE- group when
compared to groups that received either E2 or PE but not both. It has yet to be
determined, however, if this differs significantly from zero. This parallels the nonprotective infarct results of this study but is in contrast to studies cited in the introduction
of this paper, as well as several recent publications. Cai et al. (2009) found p-Akt to be
significantly upregulated in the cortex 24 hours after ischemic event; however, PTEN

was not significantly upregulated over sham until 3 days post procedure (Cai et al.,
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2009). When Scheihofer and Redmond (2009) used a PI3 kinase inhibitor, all
neuroprotection imparted to embryonic 18 day old neuron cultures against oxygen
glucose deprivation by genestein, daidzein, and equol was lost, suggesting that PEs
mediate neuroprotection, at least in part, via the Akt pathway. A recent study by
Anastasius et aI. (2009) showed that human breast cancer cells, which were positive for
estrogen receptors, had a diminished response to estrogen after a long-term genestein
exposure (10 weeks). Genestein levels within the range of those measured in humans on
high soy diets significantly inhibited E2-stimulated growth and downregulated the Akt
signaling pathway, a dominant growth stimulatory pathway in human breast cancers
(Anastasius et aI., 2009). While E2 has been shown to activate the Akt signaling
pathway, at least in part via ERa (Lee et aI., 2005), physiological doses of genestein
decreased Akt pathways in the absence of any change in ERa expression (Anastasius et
aI., 2009), suggesting that genestein could be mediating the Akt signaling pathway via a
different mechanism than does E2. Alternatives include binding to

ER~,

or extranuclear

receptors, or inhibiting tyrosine kinase, the last of which is a known action of genestein at
high doses (Akiyama and Ogawara, 1991). These papers indicate that the interplay
between E2 and PEs in regulating Akt pathways may be, at least in part, non-genomic.
However interesting the interactions may be, the results of this paper allude to the fact
that any control over the PTEN/Akt pathway seen in young animals or in cell cultures by
low level E2 and/or dietary PEs is lost in aging brains subjected to infarct. We also found
no differences in PTEN or Akt measurements between IL and CL hemispheres,
indicating that the procedure itself did not upregulate these proteins as was reported by
Omori et al. (2002).
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Is PTENIAkt expression altered in neurons or astrocytes following MCAo?
PTEN/Akt activity occurred predominantly in the neurons, instead of the

astrocytes, of the ischemic cortex following focal pMCAo. In fact, when double labeled
with Gfap, the proteins were visible in a pattern resembling the shape of the somas of
neurons and clearly outside of astrocytes. This is in agreement with Omori et ai. (2002)
and Cai et aI., 2009, in which PTEN levels were found to be elevated in cortical neurons
following tMCAo. It contrast the findings of Choi. et al (2005), in which PTEN and Akt
proteins were found in astrocytes of the hippocampus following transient four vessel
occlusion. Since PTEN immunoreactivity has been found to be high in both cortex and
hippocampus of normal rat brains (Cai et aI., 2009), the difference in tissues studied is
not likely to account for this discrepancy.

Conclusion
The hypothesis of this study was that Physiological levels of 17fJ-estradiol (E2)
and dietary soy phytoestrogens (PE) produce similar but not additive effects on primary
ischemic damage and apoptotic pathway regulation by PTENIAkt, producing an outcome
of neuroprotection in aging female systems. While E2 and PE did produce similar

effects, neither was associated with neuroprotection, thus, the hypothesis is rejected. This
study is important, however, because it adds substance to the growing body of reports
that E2 does not mitigate neuronal damage due to primary infarct and it does not
positively influence PTEN/Akt apoptotic pathways in aged female rats. It also provides a
more realistic model for putting into context the negative effects documented in
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epidemiological studies such as the WHI, in which hypoestrogenic women suffered more
frequent and detrimental stroke events when given E2 replacement. The complex
effects of E2 on the brain is yet to be determined. However enough multiple effects and
numerous neurological processes have been identified to declare it a complex set of
interactions. Which specific mechanisms predominate in a given study may largely
depend upon type and severity of injury, treatment paradigm, and age of model.
Evidence is mounting in support of the case that E2 levels seem to determine which
pathways are activated, while reproductive age and hypoestrogenic status seem to
determine how the model can respond at the classic receptor level, in mediating
inflammation, in regulating various apoptotic pathways, and/or via non-genomic
pathways, many of which are still not identified at present. Despite literature support for
the neuroprotective effects of E2 and PE, data from this study supports a lack or loss of
neuroprotection in middle aged females when treated with physiological levels of E2 via
slow release capsule and/or normal dietary levels of PE. This study is the first to
demonstrate non-neuroprotection against ischemic insult when supplementing E2 by slow
release capsule immediately post ovx. To date there have been no published findings in
which low levels of slowly released E2 via silastic capsules have been associated with
either a negative or no significant effect in middle aged females after permanent MeAo
induced by the intraluminal filament method.
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CURRICULUM VITAE

Karen Powell

CURRENT POSITION: Staff Veterinarian and Assistant Professor,
University of Louisville School of Medicine

EDUCATION
• Graduate student, University of Louisville, seeking Ph.D. in biology with emphasis
on neuroendocrinology and the molecular mechanisms of environmental
endocrine disruptors, expected completion date summer 2009 (3.75 GPA)
• M.S. in biology with emphasis on immunology and parasitology, May 1998,
Western Kentucky University (4.0 GPA)
• D.V.M., June 1994, Auburn University College of Veterinary Medicine (3.4 GPA)
• B.S. in chemistry and biology, May 1990, Western Kentucky University (3.2
GPA)

PROFESSIONAL EXPERIENCE
Clinical Experience
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Practicing Veterinarian Graystone Pet Hospital- AHAA certified (July 1994January 1997)

Associated technical skills: various orthopedic and soft tissue surgeries;
chemotherapy, total parental nutrition, and various fluid therapy
administration; advanced ocular treatments; diagnostic testing including
urinalysis, blood chemistries, plain and contrast radiography, ECGs, and
cultures with antibiotic sensitivities; jugular, peripheral venous, and arterial
catheter placements; histopathology/cytology including bacterial, fungal, and
parasite identification; preventative medicine; internal medicine; preparing
specimens for shipment to specialty diagnostic labs; patient referrals;
administration of various intramuscular and gas anesthesias; utilization of
scheduled drugs; safe handling of zoonotic pathogens; AHAA, OSHA, USDA,
and FDA compliance regulation; client education; staff management;
emergency services; and aseptic technique/quarantine.

Research Experience
Ph.D. research, University of Louisville (started March 2006) - The effects of

estrogens and/or plant based estrogens on occlusive stroke recovery in a post
menopausal Sprague Dawley rodent model
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Associated technical skills: performed ovariectomies, middle cerebral artery
occlusions, thoracotomies, and intracardiac blood collection; made and
surgically placed extended release hormone delivery implants; administered
isoflurane and ketamine/xylazine anesthesias; completed food consumption
studies; administered buprenorphine and banamine analgesics;
paraformaldehyde perfusions; tissue cryopreservation; cryostat sectioning;
immunoflourescent antibody studies; nissl staining; brain infarct analysis; cell
cultures; and utilized the biological toxin iberiotoxin.

M.S. research, Western Kentucky University (January 1997 - May 1998)Evaluation of the success of adoptive versus passive transfer of immunity against
Trypanosoma cruzi in C3HeBIFeJ mouse model.

Associated technical skills: worked with a biohazard level two pathogen;
administered intraperitoneal injections; monitored parasitemias; harvested and
processed whole spleen extracts for adoptive transfer; harvested and processed
serum for passive transfer; daily health and environment monitoring; cervical
dislocations; collection of peripheral blood samples; maintaining breeding
pairs; sexing offspring; and all aspects of rodent husbandry.
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Student research assistant, Auburn University (Summer 1992) - student employee
in Dr. Eva Sartin's lab
Associated technical skills: neurofibroma and other neoplastic cell collections,
setting up and maintaining neoplastic cell cultures, preparing media, and sterile
techniques.

Student research assistant, Auburn University (Summer 1991) - student employee
in Dr. Ralph Paxton's lab

Associated technical skills: study of the activity of the liver enzyme branched
chain alphaketoacid dehydrogenase; harvesting tissues from slaughter house;
purifying enzymes via chromatography; and enzyme identification utilizing
radioactive phosphorus

Teaching Experience (other than current position)
•

Teaching Assistantship, University of Louisville (Spring 2006)

•

Adjunct Professor, Western Kentucky University, (1998-1999)

•

Teaching Assistantship, Western Kentucky University, (1997-1998)

Courses Taught

• Biology 242 Principles of Biology lab (U of L Spring 2006)
• Biology 131 Anatomy and Physiology class (WKU 1998 - present)
• Biology 131 Anatomy and Physiology lab (WKU 1997 - present)
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•

Biology 275 Pathophysiology (WKU 2000 - 2005)

•

Biology 275 Pathophysiology Web Course (WKU 2006 - present)

•

Biology 113 General Biology class and lab (WKU 1998 - present)

•

Human Anatomy for non-science majors (WKU 1998)

•

Zoology lab (WKU 1998)

Other Appointments
•

Human Subjects Review Board (200l-present)

•

Director of the Regional Science Resource Center (2000-2007)

•

Director of the Consortium for Evidence Based Research in Rural Educational
Setting (CEBRRES) (2004-2006)

•

University Promotion and Tenure Review Committee (2006-2008)

•

Guidelines for Tenure and Promotion Revision Committee, BGCC (2005-2007)

•

Southern Association for Colleges and Schools (SACS) On Site Focus Groups
(2005)

•

WKU Faculty Search Committees - BGCC Dean (2006), Biology (2004-2005),
Health Care Information Systems (2004-2005 and 2007-2008), Geography
(2003-2004), Liberal Arts and Science Division Chair (2003 -2004), Biology
- chair of the committee (2002-2003), and History (2000-2001)

•

Task Force for Diversity (2004-2007)

•

University Assessment Committee (2003 -2005)

•

University Diversity Committee (2002 -2004)
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•

Chair of the BGCC Faculty Awards Committee and member of the University
Awards Committee (2003)

•

NASA Steering Committee for Saturday Academy Reform (2003)

•

Text book reviewer for Addison Wesley/Benjamin Cummings (2002 and 2007)

•

President's Award for Diversity Selection Committee (2002)

•

Academic Probationary Committee (Fall 2001)

Continuing Education

Conferences

• Gordon Research Conference: Environmental Endocrine Disruptors (2008)
• Society for Behavioral Neuroendocrinology Annual Meeting (2006, 2007)
• Politics of the Yellowstone Ecosystem (2006)

• NEH Landmarks of American History and Culture Workshop - Mammoth
Cave: People, Place, and History (2006)
•

The Kentucky Council on Post Secondary Education Annual Conference
(2002,2004,2005)

• Human Anatomy and Physiology Society Annual Conference (2003, 2005)
• Kentucky Academy of Science (1999, 2004)
• The Funds for the Improvement of Post Secondary Education (FIPSE)
Annual Project Directors Conference (2001, 2002, 2003)

• All One Nation Conference (2003)
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•

14th International Conference on College Teaching and Learning (2002)

•

National Association of Biology Teachers Annual Conference (2001)

•

Action Agenda Teacher Educational Summit I and II (2001, 2002)

Lectures/Workshops

•

IACUC Level II Training (2005 with online renewal in 2008)

•

Preventing Sexual Harassment (2007)

•

Being Efficient and Effective: Teaching Based on Research on Learning
(2007)

•

The One Minute Manager Meets the Monkey (2007)

•

Family Education Rights and Privacy Act (2007)

•

Why We Get Sick: The New Science of Darwinian Medicine (2007)

• Emerging Zoonotics (2006)
• Estrogen: The Mother Earth of all Hormones (2006)
• Scholarly Writing and Proposal Writing (2005)

• Blackboard Training (2003, 2005)

• Women in Science and Engineering Leadership Workshop (2004)
• Blood Borne Pathogen Training (2003)

• Teaching Portfolios (2003)
• NASA Program Review and Focus Group for Saturday and Summer
Academies (2003)

•

Legal Aspects of Instruction (2000)

• Staying Legal - Research Compliance Issues (2000)
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•

After the A ward: Administering your Grant (2000)

•

Faculty Evaluations: What I need to know for Tenure (2000)

•

Maintain Academic Quality and Still Meet Students Needs (2000)

•

Searching for Funding Opportunities Online and Preparing Grant Budgets
(1999)

Invited seminars and posters
The effects of estrogens and/or plant based estrogens on occlusive stroke
recovery in a post menopausal Sprague Dawley rodent model (Invited poster)
•

Gordon Research Conference (2008)

•

Society for Behavioral Neuroendocrinology (2007)

How I use the instructor's resource CD rom, Interactive Physiology Modules,
and blackboard to teach an all inclusive one semester A and P course
•

Human Anatomy and Physiology Society Regional Conference (2006)

Infusing your classroom with critical thinking
•

WKU (2008)

Intersexuality
•

Liberal Arts and Sciences Diversity Awareness Lecture (2005, 2006)
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A successful collaboration between middle school and post secondary education
communities the Regional Science Resource Center at the Bowling Green
Community College of Western Kentucky University
•

Kentucky Academy of Science (2004)

•

Funds for the Improvement of Post Secondary Education (FIPSE)
Annual Project Directors Conference (2003)

•

Bowling Green Community College Board of Advisors (2002)

•

Council on Post Secondary Education Action Agenda Teacher
Educational Summit II (2002)
14th International Conference on College Teaching and Learning

•

(2002)

The Consortium for evidence based research in rural educational setting
(CEBRRES)
• The Kentucky Council on Post Secondary Education Annual Conference (2005)

Using the Biology Place interactive website in general education biology classes
•

Benjamin Cummings Strategies workshop Hands on the Biology

Place, University of Kentucky (2001)

Professional and Community Service
•

Volunteer for Brigadoon State Nature Preserve (2007 - present)

•

Member of The Friends of the Clarks River (2007 - Present)
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•

The Regional Science Resource Center (2000 -2007)

•

Member of the Southern Kentucky Regional Science Fair Board (2000 2006)

•

Chair of the Science Review Committee and Institutional Review Board for
the Southern Kentucky Regional Science Fair (2000-2006)

•

Co-host of the Southern Kentucky Regional Science Fair (2003-2006)

•

Science fair judge for various schools including Drakes Creek Middle
School, North Metcalfe Elementary, and Metcalfe County High School
(2002-2006)

•

Co-director of the NAACPINASA Science and Math Saturday Academy
(2002 and 2003)

•

Grand Awards Judge for Medicine and Health at the Intel International
Science Fair, Cleveland, Ohio (2003)

•

Hosted and taught science components for various WKU K-12 programs
such as Science Olympiad, Girls in Science, Super Saturdays, Vampy,
Whitney Young Scholars, and Project Aims (2000 -2006)

•

Hosted programs with and taught science components for various community
K-12 groups including the Bowling Green Housing Authority, Clark's River
National Wildlife Refuge, Kentucky State Nature Preserves, Warren Juvenile
Detention Center, Barren River Home School Association, Gear Up, Girl
Scouts, Boys and Girls Club of Butler County, Mammoth Cave National
Park, Region Two Service Center, Green River Regional Educational
Cooperative (GRREC), NASA, and the NAACP (2000 -2006)
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•

Hosted various K-12 teacher professional development opportunities
including; Problem Based Learning in Middle School Science, Bowling
Green Elementary Teacher PD seminar, Region Two Science Academy
follow ups, and the Regional Science Resource Center / Region Two Service
Center Midsummer Science Challenge (2000 -2006)

•

National proctor for Emergency Medical Technicians (2000 -2005)

•

Co-sponsored "Funding your Best Ideas" presented by Joan Straumanis of
the Department of Education's Funds for the Improvement of Post
Secondary Education (2002)

Professional Societies

• Kentucky Veterinary Medical Association (1994 -1998 and 2006 - present)
• Society for Behavioral Neuroendocrinology (2006 - present)
• American Veterinary Medical Association (1990 -1998)
• WKU Biotechnology Center (2006-present)

• Human Anatomy and Physiology Society (2001 - present)
• Kentucky Academy for Science (2000 - 2002 and 2004 - 2005)

• National Association for Biology Teachers (2000-2002)

Honors

•

WKU Exemplary Achievement Award (2005)
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•

Auburn University College of Veterinary Medicine "Young Achiever"
Award (2004)

•

Bow ling Green Human Rights Commission Woman of the Year in Science
(2003)

•

SGA Excellence in Teaching (2002)

•

Community College Award for Public Service (2002 and 2006)

•

Outstanding M.S. graduate student (1998)

•

Presidents scholar M.S. graduate of Western Kentucky University (1998)

•

Cum Laude graduate of Auburn University College of Veterinary Medicine
(1994)

•

Whitley Ophthalmology Award Auburn University College of Veterinary
Medicine (1994)

Publications

Powell, K (1998) Evaluation of the success of adoptive versus passive transfer of
immunity against Trypanosoma cruzi. M.S. thesis.

Grants Funded

• National Wildlife Foundation Friends Group Grant (2008-2009: $10,000)
• National Wildlife Foundation, "Nature of Learning" Grant (2004-2007:
$11,000)
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•

Environmental Protection Agency, "Expanding Environmental Discovery

within
Rural Communities" (2005-2006: $30,000)
•

Environmental Protection Agency, "Expanding Environmental Discovery

within
Rural Communities" (2006-2008: $41,741)
•

The Department of Education's Funds for the Improvement of Post

Secondary
Education (FIPSE), "Regional Science Resource Center (RSRC)" (20002004:
$295,411)
•

Provost's Action Agenda, "Staff Position" (2001-2004: $58,346)

•

Provost's Action Agenda, "Midsummer Science Challenge" (2002-2003:

$18,489)

•

Provost's Action Agenda, "RSRC Vehicle" (2002-2003: $11,800)

•

NAACPINASA "Saturday Academy" (2002-2003: $5200)

•

Provost's Action Agenda, "RSRC Continuation Operational Expenses"

(2004-2006:
$25,000)

•

Teacher Education Action Agenda, "CEBRRES Pilot" (2004-2006: $86,661)

•

Provost's Action Agenda, "Outreach Assessment" (2004-2005: $11,605)

• Enterprise CommunitylBowling Green Housing Authority, 'Centering on
Science" (2004-2005: $13,000)
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